

# CURRICULUM VITAE (Full Version)

**John Lambert MD, PhD**


## Table of Contents

1- PERSONAL DETAILS .....	2
2- CURRENT AFFILIATIONS .....	2
3- TRAINING AND QUALIFICATIONS .....	2
4- CERTIFICATION .....	2
5- MEDICAL LICENSURE .....	3
6- PREVIOUS FACULTY POSITIONS .....	3
7- PROFESSIONAL MEMBERSHIPS .....	4
8- COMMITTEE MEMBERSHIPS .....	4
9- ACADEMIC TEACHING .....	5
10- HONOURS AND AWARDS .....	6
11- PEER REVIEW WORK .....	6
12- GRANT SUPPORT .....	7
13- SUMMARY OF CLINICAL TRIALS/OTHER RESEARCH EXPERIENCE .....	13
14- PRESENTATIONS/LECTURES .....	17
14- COURSE DIRECTOR .....	23
15- PUBLICATIONS .....	23
Refereed Publications .....	23
Non-Refereed Publications .....	319
16- ABSTRACTS .....	39
17- OUTREACH ACTIVITIES .....	59

## 1- PERSONAL DETAILS



## 2- CURRENT AFFILIATIONS



## 3- TRAINING AND QUALIFICATIONS

### Education

1976	B.A.	Kalamazoo College, Michigan
1981	M.D.	Michigan State University
2001	PhD	Federal University of Rio De Janeiro

### Internship & Residency (Medical/Paediatrics)

1981-1985  
Internal Medicine & Paediatrics

Strong Memorial Hospital  
Rochester, NY

### Fellowship

1987-1990

Infectious Diseases (Medical & Paediatrics)  
Strong Memorial Hospital  
Univ. of Rochester School of Medicine  
Rochester, NY

## 4- CERTIFICATION

1984 - Diplomate, American Board of Internal Medicine  
1988 - Diplomate, American Board of Paediatrics  
1991 - Diplomate, American Board of Infectious Diseases  
1992 - Certification, Paediatric Infectious Disease Society  
2002 - Diploma GUM, UK  
2003 - DFFP, UK

## **5- MEDICAL LICENSURE**

1981-1993 - New York, #150713-1  
1993 - Present - Maryland, #D45338  
2001: GMC 4785075, Specialist Register: Infectious Diseases and in Paediatrics (ID), UK  
2005 Irish Medical Council reg. no 147380 (Medicine, Infectious Diseases, GUM)

## **6- PREVIOUS FACULTY POSITIONS**

1990-1991	Instructor in Medicine and Paediatrics Univ. of Rochester School of Medicine Rochester, New York
1991-1993	Assistant Professor of Medicine & Paediatrics Univ. of Rochester School of Medicine. Director of the AIDS Educational and Training Centre for Upstate New York, Rochester, New York
1993-1996	Assistant Professor International Health JHU School of Hygiene & Public Health Joint Appointment, Dept. of Paediatrics and Adult Infectious Disease JHU School of Medicine, Baltimore, Maryland
1993-1996	Clinical Director, JHU AIDS Vaccine Evaluation Unit (AVEU) Course Director, Division of Vaccine Science, Department of International Health, School of Hygiene and Public Health Principal Investigator, Baltimore Paediatric AIDS Clinical Trial Unit (Consortium of JHMI and Univ. of Maryland), Baltimore, Maryland.
1996- 2004	Assistant Professor of Medicine and Paediatrics, Division of Clinical Research, Infectious Diseases and Peds Immunology, Institute of Human Virology, University of Maryland Biotechnology Institute, and Associate Member Center for Vaccine Development, Baltimore, Maryland. Director of the AIDS Educational and Training Centre 1996-1999).
December 1999-2007	Honorary Senior Lecturer and Locum Consultant, Units of Epidemiology and Public Health and of Immunobiology, Institute of Child Health and Great Ormond Street Children's Hospital, University College London UK

June 1999- Nov 2002	Glaxo Smith Kline Research and Development Africa Middle East Region, Director of Antivirals Greenford, Middlesex UB6 0HE, UK
September 2000-2005	Visitor, Clinical Trials Unit of the Medical Research Council, Euston Square, London, UK
March 2002-April 2003	Locum in GUM, St Mary's Hospital NHS Trust
November 2002-June 2003	Locum Consultant in Infectious Diseases, Newham General NHS Trust
April 2003-Dec. 2003	Locum SpR Chelwest, HIV/GUM, London
January 2004 to Sept 2004	SpR HIV/GUM Brighton and Sussex University Hospitals
Oct 2004-Sept 2005	SpR HIV/GUM Kings College Hospital, London

## **7- PROFESSIONAL MEMBERSHIPS**

American Society of Microbiology  
Paediatric Infectious Disease Society  
International Association of AIDS Physicians  
British HIV Association  
Children's HIV Association of the UK and Ireland (CHIVA)  
Medical Society for Study of Venereal Diseases  
Infectious Diseases Society of America  
Infectious Diseases Society of Ireland  
Fellow Royal College of Paediatrics and Child Health (UK)  
Fellow Royal College of Physicians (UK)

## **8- COMMITTEE MEMBERSHIPS**

2006 – Present	Task Force Committee – Hygiene/MRSA, Mater Misericordia University Hospital (MMUH).
2006 – Present	Research Ethics (MMUH).
2006 – Present	Biosafety Committee, University College Dublin (UCD).
2006 – Present	School of Medical Science Clinical Curriculum Board (UCD).
2007 – Present	National Aids Strategy Committee, Dept. of Health and Children, Health Service Executive (HSE), Ireland.
2007 – Present	Nasc-Care and Management Sub-committee, Dept. of Health and Children, HSE, Ireland.
2007 – Present	Health Information and Quality Authority (HIQA) HPV Vaccine Advisory Panel, Dublin, Ireland.
2007 – Present	Drugs and Therapeutics Committee (MMUH).
2007 – Present	Medical School Curriculum Committee, UCD.
2007 – Present	Dublin North Regional Strategy for the Control of Antimicrobial

	Resistance in Ireland (SARI)
2007 – Present	Infection Control Committee, (MMUH).
2008 – Present	Medical School Admission Committee, UCD.
2008 – Present	National Isolation Task Force (MMUH).
2008 – Present	International Conference on Hepatitis C- The Third Decade and Beyond, Session Chair.
2008 – Present	HSE National SARI Antimicrobial Stewardship Working Group
2008 – Present	HSE IHR Implementation: Communicable Disease Subgroup.
2008 - Present	Medicine Degree Committee 3 (MDC3)
2009 – Present	ITU Network for H1N1 Flu International.
2009 – Present	National Action Plan for Pandemic Influenza, Pandemic Influenza Emergency Management Committee, Rotunda Hospital, Ireland
2009 – Present	National Standing Advisory committee for Blood Borne Viruses, Infectious Disease Society of Ireland.
2009 – Present	International Health Regulations (IHR) Communicable Disease Sub-Group, HSE, Ireland.
2009 – Present	Dublin North Regional SARI Infection Control Committee.
2009 – Present	Clinical Curriculum Board Member.
2009 – Present	Scientific Committee Member- VI International Conference on HIV infection among women and children, Petropolis, July 8,9,10, 2009.
2010 – Present	Clinical 1 Board member.
2010 – Present	Graduate Entry to Medicine Stages 1 &2.
2010 – Present	National Standing Advisory Committee on the Prevention of Blood Borne Viruses Diseases in the Health Care Setting.
2010 – Present	HPSC Scientific Advisory Committee Emergency Management of Injuries Sub-Committee.
2011 - 2012	Co-Chair RCPI, Sexual Health Policy Group
2012 - Present	Member of HSE Sexual Health Strategy Group
2012 - Present	National Hepatitis C Treatment Programme Advisory Group (PAG)
2012 - Present	National Hepatitis C Treatment Clinical Advisory Group (CAG)
2018-Present	Single framework contract (FWC) for the provision of support services for managing expert groups in the field of (public) health Consumers, Health, Agriculture and Food Executive Agency (Chafea), an Executive Agency of the European Commission.
2019- Present	International Foundation For Sexual Health Education (IFSHE)
2019- Present	The Health Information and Quality Authority Health Technology Assessment (HTA) birth cohort testing for hepatitis C expert advisory group.
2019- Present	Member of the Centre for Experimental Pathogen Research (CEPHR) group, UCD School of Medicine

## **9- ACADEMIC TEACHING**

### **Undergraduate Teaching**

- 1. Clinical 1 UCD Medical School Curriculum, Module Co-coordinator for “History and Communications” 2006-2008**

2. Senior Lectures for undergraduate curriculum MMUH
3. **Haematology/Immunosuppression Module** in 2008- Undergraduate Medicine Programme (Stage 4-Year 4). UCD School of Medicine and Medical Science.
4. **Therapeutics and Clinical Diagnosis Module** in 2009. Lecture on Pneumonia. UCD Belfield.
5. **PUO/Tropical Medicine lecture**, 30 January 2009, Senior Medical Clinic Schedule, Final Year of Medicine Curriculum, UCD.
6. **Tuberculosis lecture**, 13 February 2009, Senior Medical Clinic Schedule, Final Year of Medicine Curriculum, UCD.
7. **Therapeutic Options for Developing World**, Public Health Medicine, Epidemiology and International Health Module, Dec 2009, UCD.
8. **Participation in the collection, management and analysis of data for a study which has ethical approval**. UCD School of Medicine and Medical Science, Research Elective MDSA 30180, SSRA 2009 Clinical Research programme
9. **Therapeutics and Clinical Diagnosis, Pneumonia**, Clinical 1 Stage 4, 15 February 2010, UCD.
10. **Haematology/ Immunosuppression Module**, 2008, 2009, 2010, UCD School of Medicine and Medical Science.
11. **Penang Clinical Attachments**: 2010 Mater Misericordia University Hospital.
12. **Principles & Practice of Clinical and Translational Research 2011 Course**. 7<sup>th</sup> September 2011, UCD, Dublin.
13. **Clinical 1 UCD Medical School Curriculum**, Module Coordinator for Professional Clinical Practice, 2009-Present.

## **10- HONOURS AND AWARDS**

1984-1985 - Outstanding House Staff Teaching Award, Dept. of Paediatrics, Strong Memorial Hospital.

## **11- PEER REVIEW WORK**

- Journal of Infectious Diseases
- Journal of Paediatrics
- Paediatrics
- Clinical Immunology
- AIDS Research
- Clinical Infectious Diseases
- Archives of Paediatrics and Adolescent Medicine
- Clinical and Diagnostic Laboratory Immunology
- Annals of Internal Medicine
- J. Acquired Immunodeficiency Syndrome
- J. Institute of Human Virology

- International J of STD and AIDS
- International Journal of Clinical Practice

Ad Hoc Review of Proposals:

- Paediatric AIDS Foundation--Grant Review
- NIDA Grant Review
- NIAID – AIDS Grant Review

Review of Publications:

- U.S.P. Drug Information Text
- American Hospital Formulary Drug Information

## **12- GRANT SUPPORT**

Principal Investigator

---

**Title: Paediatric AIDS Foundation, Student Intern Award. "Maternal Secretary Antibodies and HIV Viral Burden in Cervico-Vaginal Canal--Role in Maternal-Foetal Transmission of HIV-1 Infection."**

**Date:** 5/5/94 - 5/4/95

**Funder:** - Rutt Chuachoowong, M.D.

**Amount:** Funding Level: \$2,000

Principal Investigator

---

**Title: Baltimore Paediatric AIDS Clinic Trial Program NIAID, NIH, JHU/UMD**

**Date:** 1994-1996

**Amount:** Total Award: \$950,000

Principal Investigator

---

**Title: Paediatric AIDS Foundation, Student Intern Award. Fogarty Minority Grant Co-funded. "Assessment of Adequate Immunization Coverage in Children at Risk for HIV Infection in Rural Uganda." Student: T. Christopher Mast**

**Date:** Summer 1995

**Funder:** Fogarty Minority Grant Co-funded

**Amount:** Total Award: \$7,000

Principal Investigator

---

**Title: " Seroprevalence of STDs in Pregnant Women in an Impoverished Area of Rio De Janeiro, Brazil." Student: Dr. Valdilea de la Santos, Fiocruz, Brazil**

**Date:** Aug '95-Jul '96

**Funder:** JHU Fogarty Advanced Research Training Award Program

**Amount:** \$15,000 (No Salary)

Principal Investigator

---

**Title: AITRP: Fogarty Expansion. "Expansion of Resources in Sao Paulo and Rio De Janeiro, to Care or HIV Infected Women and Children."**

**Date:** Sep '95-Aug '98

**Amount:** \$50,000/yr. x 3 yrs.

Consultant

---

**Title: CDC Project: Phase III Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Short Course Oral Antenatal Zidovudine (“AZT”, ZDV) to Reduce Perinatal HIV Transmission, Bangkok, (Thailand Mucosal Sub study)**

Principal Investigator

---

**Title: World AIDS Foundation. "Implementation of an International Strategy to Implement the 076 Study"**

**Date:** 1998-1999

**Amount:** \$20,000

Principal Investigator

---

**Title: World AIDS Foundation. “Perinatal Education in Rio and Sao Paulo, Brazil”**

**Date:** 1999-2001

**Amount:** \$100,000

Principal Investigator

---

**Title: Chemokines as a measure of disease activity in children infected with HIV from a cohort in Rio de Janeiro, Brazil**

**Date:** 1999 – 2004

**Funder:** 5yr NIH NICHD funded R-01.

**Amount:** \$1.8 million

Co-Principal Investigator

---

**Title: John Lloyd Foundation Grant to develop manuals for HIV mother to child transmission and paediatric HIV treatment**

**Date:** 2002-2003

**Amount:** India: \$18,000.

Principal Investigator

---

**Title: “Therapeutic Drug Monitoring of Protease Inhibitors in Pregnancy as a Standard of Care.”**

**Date:** 2006

**Funder:** Bristol Myer Squibb Award/ GlaxoSmithKline (GSK)

**Amount:** €14,000 €10,000

Principal Investigator

---

**Title: A community based Hepatitis C treatment programme**

**Date:** 2006 -2008

**Funder:** Roche Pharmaceuticals

**Amount:** €150,000

Principal Investigator

---

**Title: Friends of Rotunda “Screening for Hepatitis C: a prospective study at the Rotunda Maternity Hospital Dublin Ireland”.**

**Date:** 2007

**Amount:** €200,000

Principal Investigator

---

**Title: Telzir treatment of patients co-infected with HIV and Hepatitis C.**



**Date:** 2008- 2011  
**Amount:** €826,000

Principal Investigator

---

**Title:** Woody Woodpecker Foundation to establish a MMUH/UCD link with Baphumelele Children's AIDS home, Capetown RSA  
**Date:** 2008-2009

Principal Investigator

---

**Title:** A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial comparing 24 or 48 weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103)  
**Start/End dates:** 01/01/2008 to 01/06/2014  
**Funder:** Gilead  
**Amount:** €8,675.58 per completed subject.

Principal Investigator

---

**Title:** Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregnANt women (PANNA) Eudra CT number 2008-006158-16  
**Start/End dates:** 01/01/2011 to 31/12/2016  
**Funder:** Radboud University Nijmegen Medical Centre, The Netherlands  
**Amount:** €2,800 per subject.

Principal Investigator

---

**Title:** TDM in pregnancy study  
**Start/End Dates:** 1/6/2011 to 31/12/2015  
**Funder:** Janssen  
**Amount:** €18,000

Principal Investigator

---

**Title:** AI444-026 : An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C-  
**Start/End Dates:** 1/8/2011 to 31/02/2017  
**Funder:** BMS  
**Amount:** Funding 5,863.94 per study subject. Study currently recruiting

Principal Investigator

---

**Title:** BMS 444046-A Long-Term Follow-up Study of Subjects who Participated in A Clinical Trial in Which BMS-650032 and/or BMS-790052 was Administered for the Treatment of Chronic Hepatitis C.  
**Start/End Dates:** 1/01/2012 to 31/04/2017  
**Funder:** BMS  
**Amount:** - Currently recruiting- Funding €16,069.12 for 4 study subjects

Principal Investigator

---

**Title:** Audit of HIV infected children in East London, RSA.  
**Date:** 2012- present  
**Funder:** ViiV

**Amount:** by £228,000

Principal Investigator

---

**Title:** A phase III, randomised, double-blind and placebo controlled study of BI 207127 , in combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection

**Start/End Dates:** 1/03/2012 to 31/12/2014

**Funder:** Boehringer Ingelheim

**Amount:** €4213 per subject.

Principal Investigator

---

**Title:** Paediatric ARV Software Development Project- South Africa

**Start/End Dates:** 9/2/2012 to 31/12/ 2014

**Funder:** ViiV

**Amount:** £228,000

Principal Investigator

---

**Title:** Protocol AI447-028: A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection-

**Start/End Dates:** 1/08/2012 to 31/02/2014

**Funder:** BMS

**Amount:** Funding €32,309 for 4 patients recruited into study

Principal Investigator

---

**Title:** Global Adolescent HIV Research Project: The Passages Project

**Date:** 2014- present

**Funder:** ViiV

**Amount:** €237,333

Principal Investigator

---

**Title:** Homeless HepCheck

**Date:** 2014- 2016

**Funder:** Merck/ AbbVie joint funding

**Amount:** €75,000.

Principal Investigator

---

**Title:** PMTCT/ young adult ARV, RSA, PHASE 2

**Date:** 2014- present

**Funder:** Funded by ViiV

**Amount:** £150,000.

Principal Investigator

---

**Title:** Global Adolescent HIV Research Project: The Passages Project Phase 2.

**Date:** 2014- present

**Funder:** ViiV

**Amount:** £200,000.

Principal Investigator

---

**Title:** Audit of HIV infected PASDP phase 2, RSA, Zambia, Kenya and Swaziland.

**Date:** 2014- present  
**Funder:** Janssen  
**Amount:** €198,175

Principal Investigator

---

**Title:** Audit of HIV infected children PASDP phase 2, RSA, Eastern Cape  
**Date:** 2014- present  
**Funder:** ViiV  
**Amount:** €199,953

Principal Investigator

---

**Title:** PASDP (Paediatric ARV Software Development Project) Phase 2, South Africa  
**Date:** 2014- 2017  
**Funder:** ViiV  
**Amount:** £ 199,953

Principal Investigator

---

**Title:** PASDP Expansion (Paediatric ARV Software Development Project) Zambia, Swaziland, Kenya, South Africa  
**Date:** 2014 - 2017  
**Funder:** Funder: Janssen

A Principal Investigator

---

**Title:** AHIV international (PASSAGES Project)  
**Start/End Dates:** 01/01/2014 to 31/12/2016  
**Funder:** ViiV  
**Amount:** €237,333  
**mount:** € 198,175

Principal Investigator

---

**Title:** HEP CARE (Ireland) (Hepatitis C Project)  
**Date:** 2014 - 2016  
**Funder:** Abbvie, BMS & Gilead Sciences  
**Amount:** € 50,000; €58,000 and €38,000

Principal Investigator

---

**Title:** Homeless HepCheck (Hepatitis C Project)  
**Start/End Dates:** 2014 - 2016  
**Funder:** Abbvie and MSD  
**Amount:** € 50,000 and €25,000

Principal Investigator

---

**Title:** HepCare project. Hepatitis C outreach project in collaboration with primary care  
**Date:** 2014- 2016  
**Funder:** Funded by BMS  
**Amount:** €58,500.

Principal Investigator

---

**Title:** Prevention of Mother to Child Transmission (PMTCT) Project, South Africa  
**Date:** 2015 -2016

**Funder:** ViiV  
**Amount:** £ 150,000

Principal Investigator

---

**Title:** HEP CARE EUROPE Project.  
**Date:** 2016 -2019  
**Funder:** Third Health Programme EU  
**Amount:** commission funded project. €1,800,000.00

Principal Investigator

---

**Title:** Hepatitis C in an Irish Prison Setting: Seek & Treat  
**Start/End Dates:** 1/05/2016 to 31/4/2019  
**Funder:** AbbVie  
**Amount:** €110,000

Principal Investigator

---

**Title:** An open label study of the safety and efficacy of FDC Zepatier (elbasvir and grazoprevir +/- Ribavirin) administered in a community based setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with compensated F3 and F4 liver disease.  
**Funder:** MSD (Merck, Sharp & Dohme)  
**Length of study:** 2 yrs  
**Study budget:** US\$200,000 (approx)

Principal Investigator

---

**Title:** INTEGRATE: Joint Action on integrating prevention, testing and linkage to care strategies across HIV, viral hepatitis, TB and STIs in Europe  
**Title of WP:** WP7- Improving the use of ICT tools and Partner Notification in combination prevention for HIV, viral hepatitis, TB and STIs  
**Role:** work package leader  
**Start and end dates:** 1/9/2017- 31/8/2020  
**Funder:** 80% co-funding under the third EU Health Programme  
**Funding amount:** €150,000 (overall project value €2,400,000 including over 30 partners)

Principal Investigator

---

**Title:** HEP CURE  
**Funder:** Gilead  
**Length of study:** 01/08/2018- 31/07/2019  
**Study budget:** €90,149.24

Principal Investigator

---

**Title:** HepCare Plus  
**Funder:** Health Service Executive Ireland  
**Length of study:** 01/01/2019-31/13/2020  
**Study budget:** €125,494.25

Principal Investigator

---

**Title:** Clinic 6 Micro-Elimination Project  
**Funder:** Gilead  
**Length of study:** 01/09/19- 31/08/20  
**Study budget:** €25,295.00

Principal Investigator

---

**Title: OPTIMISE: YOUTH PREVENTION, COMMUNITY STI SERVICES, INTEGRATED HEPATITIS C CARE**

**Funder:** SRSS (Structural Reform Support Service) of the European Commission.

**Length of study:** Commenced 1<sup>st</sup> Nov 2019 (3 year project)

**Study budget:** €443,060

Principal Investigator

---

**Title: North Dublin Integrated Community STI Service**

**Funder:** Slainte Care

**Length of study:** 01/01/2020-31/12/2020

**Study budget:** €203,491

Principal Investigator

---

**Title: Anticipate Covid-19 Study**

**Funder:** Health Research Board

**Length of study:** 11/05/20- 10/11/21

**Study budget:** €199,839

### **13- SUMMARY OF CLINICAL TRIALS/OTHER RESEARCH EXPERIENCE** **(see publication and abstract section for details of studies):**

- ACTG 064: A Phase 1 study of the safety and immunogenicity of DDI administered twice daily to HIV infected adults. (Clinical director of Study; PI Dr Ray Dolin).
- ACTG 185: A Phase 3 Efficacy Trial of HIVIG administered to HIV infected pregnant women and their new-borns. (Principal Investigator of the study).
- ACTG 218: A Phase 1/2 Safety and Immunogenicity study of HIV vaccines administered to HIV infected children. (PI, Study Co-Chair)
- ACTG 326: A Phase 1/2 Safety and immunogenicity study of HIV vaccines administered to HIV exposed children (PI, Study Chair)
- AVEG 102: A Phase 1 study of an HIV vaccine (microgenesys) administered to HIV infected Pregnant women. (PI, Study Co-chair)
- AVEG 104: A Phase 1 study of an HIV vaccine (genentech) administered to HIV infected pregnant women (PI, study Co-Chair)
- AVEG 018: A Phase 2 study on an UBI microparticulate oral vaccine administered to HIV low risk seronegative adults. (PI, study chair)
- Biovir Study: A Phase 1/2 study of Combivir administered to HIV infected pregnant women and their new-borns in an outpatient clinic in Rio de Janeiro, Brazil. (PI, study Co-Chair).
- Hepatitis B Study: A Phase 1/2 study of the administration of a Hepatitis B vaccine to new-borns born to HIV infected mothers, Sao Paulo, Brazil. (study PI)
- Penta 10/MRC: A Phase 2 study of the administration of IL-2 to HIV infected children followed as part of the European Paediatric HIV network. (study co-chair)
- Brazil DDI Study: A Phase 1 study of the bioequivalence of once daily versus twice daily DDI administered to HIV infected children. (study PI)

- Fiocruz Study: Establishment of a high risk gay men's cohort, assessing risk of acquisition of STD's in this population followed at the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil (Co investigator)
- Trichomonas Study: Evaluation of the prevalence of asymptomatic carriage of trichomonas in men attending the STD clinic at the Monroe County Health Department, Rochester NY
- Herpes Study: Evaluation of a rapid HSV test kit in a population of STD patients followed at the Monroe County STD clinic, Rochester NY (co-investigator).
- STD in Pregnant Women Study: Establishment of a Cohort of High risk pregnant women at Fernandez Figeroia Institute, Rio de Janeiro, Brazil, and measurement of prevalence of STDs in this population. Comparison of standard culture techniques with LCR/PCR for GC and chlamydia. (PI, student mentor)
- Uganda Peds vaccine study: Assessment of attitudes to vaccination in a paediatric clinic in rural Uganda (student mentor)
- HIV and syphilis study: Evaluation and characterization of pregnant women co-infected with syphilis and HIV in a pre-natal clinic in Rochester NY (study PI)
- Paracoccidiomycosis and HIV: Characterization of the association of paracoccidio and HIV (study co-investigator).
- Post transfusion hepatitis C study: Prevalence and incidence of Hepatitis C in a cohort of transplant patients followed at the Federal University of Rio de Janeiro, Brazil. (thesis advisor)
- Rapid HIV testing Study-Rio de Janeiro and Port of Spain, Trinidad and Tobago: Study of the feasibility of HIV rapid testing used in labour and delivery for the rapid diagnosis and treatment of HIV infected pregnant women. (study PI)
- CDC cervical lavage study Measurement of mucosal antibody from cervical lavage specimens taken from HIV infected pregnant women who were part of the CDC/Thai AZT MTCT study. (Consultant to CDC for mucosal immunity study, thesis advisor for student PhD thesis Dr Rutt)
- Bacillary angiomatosis study: Study of the characterization of relationship and manifestations of HIV and bacillary angiomatosis co-infected patients from a series of hospitals in Rio de Janeiro, Brazil (co-investigator).
- MCTC cohort Chennai: Establishment and characterization of a cohort of HIV infected pregnant women followed at a tertiary Care centre, YRG, in Chennai, India (student mentor, co-investigator).
- Paediatric HIV cohort Chennai: Establishment and characterization of a cohort of HIV infected children followed at the YRG medical clinic in Chennai, India (student mentor, co-investigator).
- MTCT cohort Rio: Establishment of a cohort of HIV infected pregnant women from the maternities of the Federal University of Rio de Janeiro, Brazil (co-PI).
- Paed AIDS cohort Rio: Establishment of a cohort of HIV infected and exposed children followed at the Federal University of Rio de Janeiro, Brazil, (co-PI).
- Seroprevalence of STD in PG women cohort Rio: Establishment and characterization of STD's found in a cohort of pregnant women followed at the State University of Rio de Janeiro, Brazil, (study co-PI and thesis advisor).
- Hepatitis G study Rio: Assessment of the prevalence of hepatitis G in a cohort from the Federal University of Rio de Janeiro, Brazil. (study co-PI and thesis advisor)
- Pneumococcal vaccine study in HIV infected adults: Assessment of the safety and immunogenicity of a conjugate Pn Vaccine in adults with symptomatic HIV infection. (study PI)
- Transmission of HIV Subtypes in MTCT: Evaluation of the fidelity of transmission of chimeric HIV from

- mother to child in the Rio de Janeiro cohort.  
(study co-PI)
- Quest study--quad therapy: Thymic reconstitution following HAART therapy in a cohort of adults followed in a multicentred GSK sponsored study (co-investigator).
- Genotypic analysis of HIV infected children: Establishment of cohort and evaluation of genotypic resistance, following therapy, in children followed in the specialty clinics of the Federal University of Rio de Janeiro Brazil. (PI).
- Protocol A4001050: A multi-centre open label expanded access trial of Maraviroc. Mater Misericordiae University Hospital (MMUH): (PI).
- Protocol M05-730: A phase III, randomised, open label, study of Lopinavir/ritonavir tablets versus soft gel capsules and once daily versus twice daily administration, when co-administered with NRTIs in antiretroviral naïve HIV-1 infected subjects. MMUH: (PI).
- Protocol AI424136: A phase IV, open-label, randomised, multicentre trial assessing the efficacy of a treatment maintenance phase with unboosted vs. boosted Reyataz after an induction phase with Reyataz and Ritonavir in treatment naïve HIV patients (the INDUMA Study)
- Euro resistance Study: Strategy to control spread of HIV drug resistance. Official European Commission supported programme. (Co-Investigator)
- TDM study Therapeutic drug monitoring: use in HIV infected pregnant women. MMUH/Rotunda Hospital, Dublin. (PI), various funders. BMS (€25,000); BMS (€52,700); Janssen (€24,000).
- Immune response to Tuberculosis in people with and without HIV infection. MMUH: (PI).
- Protocol M06-802: A phase III, randomised, open label study of Lopinavir/ritonavir tablets 800/200mg once-daily versus 400/100mg twice-daily when co-administered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in antiretroviral-experienced, HIV-1 infected subjects
- Protocol CNA1095586: Study of Once Daily Abacavir/ Lamivudine versus Tenofir/ Emtricitabine, administered with Efavirenz in antiretroviral naïve HIV-1 infected adult subjects., BMS, €25,000
- Barriers to and enablers of hepatitis C screening and treatment among current or former injecting drug users in Ireland: A qualitative study from two perspectives. Co-investigator with Dr Walter Cullen, PI.
- Community Based Hepatitis C Treatment Study: Thompson Street Centre, Dublin 1. (PI) ROCHE, €151,203.
- Dublin HIV Cohort Study: Recruitment of patients with HIV from the major teaching hospitals in Dublin. (Co-Investigator)
- Telzir/Hepatitis C Study: Phase 4 study of Telzir treatment in patients with Hep C coinfection (PI), GSK, €243,621.91

<u>AI 447-016</u>	A phase 2a/2b study of BMS-650032 in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. BMS, €5,492 per subject.
<u>S-COLLATE Study</u>	A Multicentre, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects with HbeAg positive or HbeAg negative Chronic Hepatitis B Receiving Therapy with PEGASYS® (Peginterferon alfa-2a 40 KD), Roche, €500.
<u>Protocol GS-US-196-0103</u>	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial comparing 24 or 48 weeks of GS-9190, in Combination with Peginterferon Alpha 2a and Ribavirin, to 48 weeks of Peginterferon Alpha 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection, GILEAD, €44,819.
<u>Investigation into the reasons for HIV infected women not following up for their own care postpartum.</u>	MMUH/Rotunda.PI., AbbVie, €25,000
<u>PANNA study</u>	Study on Pharmacokinetics of newly developed Antiretroviral agents in HIV-infected pregnant women (PANNA), University of Radboud, The Netherlands, €7,000.
<u>AI444-026</u>	An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C, BMS, €9,684.11 per patient.
<u>AI447-028:</u>	A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection, BMS, €32, 309 for 4 patients.
<u>BI1241.20</u>	A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection, Boehringer Ingelheim, €18,158.
<u>P15-702</u>	Real World Evidence of the Effectiveness of ABT -450- Ombitasvir, Dasabuvir, Ribavirin in patients with Chronic Hepatitis C – An Observational Study in Ireland
<u>The BICSTAR Study</u>	Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/ Emtricitabine /Tenofovir Alafenamide (B/F/TAF) 4/2/2019- ongoing €1,290 per study subject



## **14- PRESENTATIONS/LECTURES**

1. **TB and HIV: from Africa to the EU**, Mar 2006  
TB – A Global Disease, International Approaches for control and prevention and a model programme for Ireland, World TB Day, Post Graduate Centre, Mater Misericordiae Hospital, Eccles St, Dublin 7.
2. **STIs in Pregnancy**, Mar 2006  
Society for the Study of Sexually Transmitted Diseases in Ireland, Spring Meeting, Castleknock, Dublin 15.
3. **N5N1 – the bird flu virus – what it is and how it emerged**, Jun 2006  
Pandemic Flu Risk: facts and fictions, an information seminar for healthcare professionals, Westbury Hotel, Dublin.
4. **Pregnancy and Viral Hepatitis**, Jun 2006  
The European Association for the Study of the Liver. Course 6: Clinical Hepatology, Dublin Castle.
5. **Epidemiology and Clinical Manifestations of HIV/AIDS**, Feb 2007  
University of Dublin Trinity College.
6. **The role of antivirals in the management of seasonal influenza in Ireland**, Sep 2007  
Influenza Forum, Trinity College Dublin, Dublin, Ireland.
7. **STDs in Pregnancy: Evaluation and Treatment of Mother and Child**, Nov 2007  
Infection in Pregnancy and the Neonate: Setting Up the Network for Diagnosis and Treatment. The Rotunda Hospital, Dublin.
8. **TB and STD's**, December 2007  
Irish Society of Public Medicine, Ardee, Co. Louth, Ireland.
9. **The PreTravel Consultation & Infectious Diseases**, April 2008  
Allen & Hanburys, Interactive Case Study Workshop, Ardboyne Hotel, Navan, Co. Meath, Ireland.
10. **HIV Exposure and Post Exposure Follow up Care for the Patient Following Sexual Assault/Rape**, April 2008  
Faculty of Nursing & Midwifery, Royal College of Surgeons in Ireland, Dublin.
11. **Clinical Management**, May 2008  
Programme for Training Hepatitis B Contact Tracing & Guidelines for Public Health Management, Stewarts Hospital Palmerston, Dublin.
12. **Predictors of bilirubin in HIV-1 Infected subjects on Atazanavir**. Infectious Diseases Society of Ireland, Inaugural Meeting, Dublin, June 2008.
13. **Sexual Health- Prevention Interventions**, Annual Lecture Female Health, Nov 2008. Westbury Hotel, Dublin.
14. **Promoting Sexual Health in a Changing Ireland**, Public meeting Chair, Royal College of Physicians of Ireland, Dublin, 8<sup>th</sup> December 2008.

15. **Hepatitis C protects against hyperbilirubinaemia in patients on Atazanavir.** British HIV Association Spring Meeting, Belfast 2008.
16. **Platelet function and HIV: a case-control study.** Infectious Diseases Society of Ireland Meeting, 2008.
17. **Dealing with STIs in General Practice,** GP lecture, 29 April 2009, New park Hotel, Kilkenny.
18. **HPV vaccination: targeting a challenging virus,** IDSI 2009 Symposium, 11 June 2009.
19. **Workshop on HIV and HPV vaccination: how to generate protective immunity,** GSK Satellite Symposium “*Focussing on the important needs of cervical cancer vaccination*”, Infectious Diseases Society of Ireland Annual Scientific Meeting. 11-12 June 2009
20. **International perspectives about HIV prevention from mother to child.** VI International Conference on HIV infection among women and children and children. Rio de Janeiro 8-10 July 2009.
21. **Safety in a long period of time of children exposed to anti-retrovirals in uterus.** VI International Conference on HIV infection among women and children and children. Rio de Janeiro 8-10 July 2009.
22. **HBV and HCV in pregnant women infected by HIV.** VI International Conference on HIV infection among women and children and children. Rio de Janeiro 8-10 July 2009.
23. **Update on HIV,** 8<sup>th</sup> Nordic HIV Conference, 4<sup>th</sup> -5<sup>th</sup> November 2009, Croke Park Conference Centre, Dublin, Ireland.
24. **What should I do when I have a patient with a urinary catheter?** Dublin North Regional SARI Infection Control Committee Infection Prevention and Control Seminar. 2 December 2009
25. **Odyssey of the Mind, Evolving Challenges of HIV.** Chair Person. 11<sup>th</sup> March 2010, The Westbury Hotel, Dublin 2.
26. **Male and Female Health Conference, Update on STIs,** 20<sup>th</sup> March 2010, Rotunda Hospital, Dublin.
27. **The Voice of Young People, A Report on Attitudes to Sexual Health.** 22<sup>nd</sup> March 2010, Studio 1, The Science Gallery, Trinity College Dublin.
28. **Maternal Medicine: Medical Complications in Pregnancy, HIV in Pregnancy,** 12<sup>th</sup> May 2010, Royal College of Obstetricians and Gynaecologists, London.
29. **HPV Vaccine,** 21<sup>st</sup> October 2010, Irish Society of Community and Public Health Medicine, Westbury Hotel, Dublin.
30. **High Density lipoprotein cholesterol and 10-year cardiovascular risk in HIV-infected patients.** 12<sup>th</sup> International Workshop on adverse drug reactions and co-morbidities in HIV, London, October 2010.
31. **HIV in pregnancy,** 23<sup>rd</sup> November 2010, RCOG Annual Professional Development Conference, Royal College of Obstetricians and Gynaecologists, London.

32. **Maternal Medicine: Medical Complications in Pregnancy, HIV in Pregnancy.** 28<sup>th</sup> March 2011, Royal College of Obstetricians and Gynaecologists, London.
33. **Predictors of 25(OH)D and seasonal changes in PTH in HIV-infected subjects.** Moderated presentation. Conway Festival of Research, U.C.D. Sep 2011.
34. **An Overview of Lyme Disease- Diagnosis, Prevention and Control,** 6<sup>th</sup> October 2011, Tullamore Court Hotel, Dublin.
35. **HIV 30 Years On,** 24<sup>th</sup> March 2012. Irish Student Health Association 2012 Conference and AGM, Herbert Park Hotel, Ballsbridge, Dublin 4.
36. **GUM in pregnancy, HIV in pregnancy.** 26<sup>th</sup> March 2012. Maternal Medicine: Medical Complications in Pregnancy, Joint RCOG/BMFMS Meeting, Royal College of Obstetricians and Gynaecologists, London.
37. **Treating Pregnant Hepatitis B Patients with Anti-virals.** 13-14 April, 2012. Irish Society of Gastroenterology Spring Meeting, Hotel Kilkenny, Ireland.
38. **Asymptomatic Screening of STI's.** 30<sup>th</sup> May 2012, Royal College of Physicians of Ireland, Dublin.
39. **Seasonal Changes in and predictors of 25 (OH)D and PTH in HIV-1 infected subjects.** Infectious Diseases Society of Ireland, Dublin, June 2012.
40. **HIV in Pregnancy.** Royal College of Obstetricians and Gynaecologists, Maternal Medicine: Medical Complications in Pregnancy. 5-6 March 2014, RCOG, London, UK.
41. **The Ebola Virus Disease Outbreak- update and implications for Health Professionals.** Faculty of Occupational Medicine, 2014 Autumn Conference, 3<sup>rd</sup> October 2014.
42. **The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 infected patients.** 12<sup>th</sup> International Workshop on adverse drug reactions and co-morbidities in HIV.
43. **The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 infected patients.** Infectious Diseases Society of Ireland Annual Meeting, Dublin, June 2011.
44. **Predictors of 25(OH)D and seasonal changes in PTH in HIV-infected subjects.** 13<sup>th</sup> European AIDS Society Conference, Serbia Nov 2011.
45. **High-density lipoprotein cholesterol and 10-year cardiovascular risk in HIV-infected patients.** Infectious Diseases Society of Ireland Annual Meeting, Dublin, June 2011.
46. **High-density lipoprotein cholesterol and 10-year cardiovascular risk in HIV-infected patients.** Infectious Diseases Society of Ireland Annual Meeting, Dublin, June 2011.
47. **Predictors of 25(OH)D and seasonal changes in PTH in HIV-infected subjects.** 13<sup>th</sup> European AIDS Society Conference, Serbia Nov 2011.
48. **Predictors of 25 (OH)D and seasonal changes in PTH in HIV-infected subjects.** Dublin Academic Medical Centre, Young Investigators Research Symposium, May 2012.

49. **Making Integrated Care Happen.** Hepatitis C Masterclass, Catherine McAuley Research & Education Centre, Nelson St, Dublin 26<sup>th</sup> September 2015
50. **Clinical Research: Using data and audit to influence clinical practice.** Rotunda Hospital Research Day, Dublin, 2<sup>nd</sup> June 2016
51. **Presentation “Expert Patient”** Irish Street Medicine Symposium 2016, Western Gateway Building, University College Cork. Saturday 24<sup>th</sup> September 2016
52. **Lyme Disease and Co-infections. Results from a Dublin Clinic treating Scottish, English and Irish Patients 2014-2016** Vis-à-vis Symposiums, London, England, Saturday 1<sup>st</sup> Oct 2016
53. **Lyme & Co-infections.** Mater Misericordiae University Hospital GP Study Day, Catherine McAuley Research & Education Centre, Saturday 4<sup>th</sup> March 2017
54. **Presentation HIV, Hepatitis B and C in Pregnancy.** Maternal Medicine: Medical Complications in Pregnancy, Royal College of Obstetricians & Gynaecologists, Regents Park, London. 6-7 April 2017
55. **Peer Support Masterclass,** The Pillar Room, Rotunda Hospital, Dublin 1. 5<sup>th</sup> May 2017
56. **Lyme & co-infections: Bringing Science from Bench to Bedside.** Presentation Lyme and Co-infections: The Irish Experience, 7<sup>th</sup> ILADS European Conference. Paris, France May 19-20, 2017
57. **An Audit of 100 Patients from an Infectious Disease Practice,** Dublin Ireland, with Lyme- Like Symptoms. Mater Private Study Day 2017 (No date or venue)
58. **Chronic Lyme & Co-Infections including Anaplasma: The Irish Experience.** GP Training Day. Catherine McAuley Research & Education Centre, 21 Nelson St. Dublin 7, 2017 (No date)
59. **Lyme Disease Conference: Diagnosis & Treatment of Lyme-Like Co-Infections.** Sheraton Hotel, Athlone, Ireland. 12<sup>th</sup> March 2017
60. **Upregulation Underlying Infections by Vaccination & Major Trauma.** International Conference on Chronic Pathologies Saturday 9<sup>th</sup>-Sunday the 10<sup>th</sup> of September, Antwerp, Belgium.
61. **Hep C Making it a Rare Disease for those Most at Risk.** Irish Street Medicine Conference, University College Dublin. 29<sup>th</sup> September 2017
62. **HepCheck: Homeless, Hep C & Competing Priorities in Dublin.** European General Practice Research Network 85<sup>th</sup> Meeting of the EGPRN: Croke Park Conference Centre, Dublin, October 20<sup>th</sup> 2017
63. **Lyme Disease Expert Day: Lyme & Co-Infections the Irish Experience.** Catherine McAuley Research & Education Centre, 21 Nelson St. Dublin 28<sup>th</sup> October 2017.
64. **No one gets left behind:** Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community in Dublin, Ireland- Symposium. 2<sup>nd</sup> European Conference on Addictive Behaviours and Dependencies Lisbon Addiction Conference, 24-26 October 2017, Lisbon, Portugal

1. *Hepcheck: To enhance HCV screening of PWID* **John S. Lambert**, Carol Murphy, Dee L. Menezes, Walter Cullen, Tina McHugh, Geoff McCombe, Austin O'Carroll- Lisbon 2017
2. *HepLink: To integrate primary and secondary care by developing an integrated model of HCV care for PWID.* Davina Swan, Eileen O'Connor, Geoff McCombe, John S. Lambert<sup>2</sup>, Walter Cullen.
3. Hepfriend: Developing and cost evaluating a community peer support model to improve access to HCV treatments for PWID. Tina McHugh, Lar Murphy, Nicola Perry, Belinda Nugent, Passerose Mantoy-Meade, John S. Lambert
65. **ILADS 18<sup>th</sup> Annual Conference *Ehrlichia/Anaplasma: Clinical Picture and Treatment Outcomes in Ireland.*** Boston Park Plaza Hotel, Boston, MA Boston. Saturday, 11 November 2017
66. **Royal College of Obstetricians & Gynaecologists.** Maternal Medicine Complications in Pregnancy 1-2 March 2018
67. **College of Psychiatrists of Ireland.** *Lyme in Ireland: Diagnostic Challenges, Treatment, Challenges and Neuropsychiatric complications.* Phoenix Suite. Ashling Hotel, Parkgate St, Dublin 8, Ireland. 26<sup>th</sup> April 2018
68. **2017 ILADS Annual Scientific Conference, Fundamentals Course, & New Perspectives on Lyme Challenges**
69. **The Returning Traveller Conference name of presentation?** 10<sup>th</sup> May 2018, Catherine McAuley Research & Education Centre, 21 Nelson St, Dublin 7, Ireland.
70. **Lyme & Co-infections Conference** 2<sup>nd</sup> June 2018, Astra Hall, Student Centre, UCD, Bellfield Dublin 4, Ireland.
71. **Drug-related Infectious Diseases (DRID) HepCare Europe**, 2018 Expert Meeting 24-25<sup>th</sup> September 2018 EMDDA, Lisbon, Portugal.
72. **Irish Street Medicine Symposium**, Trinity College School of Medicine. Institute of Population Health, School of Medicine, Trinity College Dublin, Tallaght Cross, Dublin 24. Ireland, 28th September 2018.
73. **Innovate to Eliminate: Working in Partnership to Eliminate Hepatitis C. Homeless Outreach Services** 18<sup>th</sup> of October 2018. The Alex Hotel, 41-47 Fenian St, Dublin 2, Ireland.
74. **Telephone Triage Nurses Section Conference *Lymes Disease - An Overview*** 3rd October 2018 The Richmond Education and Event Centre, North Brunswick Street, Dublin 7
75. **RCGP Lyme Disease, poTS, Syncope and IBD- easily missed diagnoses. Challenges in the diagnosis and treatment of Lyme 7 Co-infections**, 12th of November 2018. Birmingham Marriott Hotel, Birmingham, UK
76. **HepCare: Lessons learned on HCV testing and treatment among key risk groups, including drug users and homeless, through outreach to the community and integration of primary and secondary care services**, Oral presentation Integrate Satellite session HepHIV 2019, January 28-30, Bucharest, Romania.

77. **RCOG Maternal Medicine: Complications in Pregnancy.** *HIV, Hepatitis B and C in Pregnancy.* Thursday 7<sup>th</sup> of March 2019 Royal College of Obstetricians & Gynaecologists, London, United Kingdom.
78. **Infectious Diseases Society of Ireland 12<sup>TH</sup> Annual Scientific Meeting** *Demographics and treatment outcomes of patients with chronic Hepatitis C infection attending a tertiary level hospital in the era of unrestricted access to direct-acting antivirals.* 17<sup>th</sup> of May 2019, Royal College of Surgeons Ireland (RCSI), Dublin, Ireland.
79. **Mater ID: Working Locally, Impacting Globally.** 21<sup>st</sup> May 2019, Catherine McAuley Research and Education Centre, 21 Nelson Street, Dublin 7.
80. **Lyme Patient Led Conference** *Challenges of Tick Borne Diseases* , 25<sup>TH</sup> OF May 2019, Tullamore Court Hotel, Tullamore, Co. Offaly.
81. **1<sup>st</sup> European Crypto Infections Scientific Conference.** *Cryptic Infections in Pregnancy.* 31st May-1<sup>st</sup> of June 2019. The Pillar Room, Rotunda Hospital, Dublin, Ireland.
82. **ILADS 9<sup>th</sup> European Scientific Conference,** *Lyme Disease- Environmental Disease of the 21<sup>st</sup> Century, Congenital Infections in Pregnancy, with special focus on Borrelia,* 8<sup>th</sup> of June 2019 Madrid, Spain.
83. **HepCare Europe Masterclass NOHep- Towards Elimination Masterclass** 19<sup>th</sup> of June 2019, Catherine McAuley Research and Education Centre, 21 Nelson Street, Dublin 7
84. **HepCare Europe Transitioning HCV Care into the community** Journee Hepatite 16<sup>th</sup> September 2019, Paris, France
85. **Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST'** Lisbon Addictions Conference 2019 24<sup>th</sup> October 2019 Lisbon, Portugal
86. **Antimalarial agents** on 18th November 2019 in Room B005 of UCD Health Sciences; Belfield, Dublin 4.
87. **Helminths and antihelmintic agents** on 20th November 2019 in Room B005 of UCD Health Sciences. Belfield, Dublin 4.
88. **Lyme Disease and PoTS** on 9<sup>th</sup> of December 2019 Institute of Child Health, UCL, Great Ormond Street, 30 Guildford Street, London WC1N 1EH
89. **Will Ireland reach the WHO elimination target by 2030?** 29<sup>th</sup> February 2020 ICGP Hepatitis C Conference, Davenport Hotel, Dublin 2.
90. **Maternal Medicine: Medical Complications in Pregnancy** 5th March 2020 Royal College of Obstetricians and Gynaecologists, London, United Kingdom
91. **Crypto Infections Conference** 26-27<sup>th</sup> September 2020 Online

## **14- COURSE DIRECTOR**

92. STI Foundation Courses. 2006- Present. Course Director. Courses are run 2/3 times yearly. BASHH endorsed course, accredited in Ireland with the ICGP and An Board Altranais. Course currently held at the Catherine Mc Auley Centre, 21 Nelson St, Dublin 7, Ireland.
93. The 2011 National PEP Conference. 1<sup>st</sup> April 2011. Croke Park Conference Centre, Dublin, Ireland.
94. The 2013 National PEP Conference. 19<sup>th</sup> April 2013. Rotunda Hospital, Parnell Square, Dublin, Ireland.
95. Viral Haemorrhagic Fevers & Other Highly Infectious Diseases Meeting. 29<sup>th</sup> May 2013. Catherine Mc Auley Education & Research Centre, 21 Nelson St, Dublin 7, Ireland.
96. Ebola Conference. 12<sup>th</sup> November 2014. Catherine McAuley Education & Research Centre, 21 Nelson St, Dublin 7, Ireland.
97. The 2015 National PEP Conference. 8<sup>th</sup> May 2015. Catherine McAuley Education & Research Centre, 21 Nelson St, Dublin 7, Ireland.
98. The 2017 National PEP Conference 26<sup>th</sup> April 2017, The Pillar Room, Rotunda Hospital, Dublin 1.
99. The Returning Traveller Conference 10<sup>th</sup> May 2018, Catherine McAuley Research & Education Centre, 21 Nelson St, Dublin 7, Ireland.
100. Lyme & Co-infections Conference. 2<sup>nd</sup> June 2018, University College Dublin, Belfield, Dublin 4, Ireland.
101. 1<sup>st</sup> European Crypto Infections Scientific Conference. The Science behind Lyme Disease and Co-Infections. 31<sup>st</sup> May- 1<sup>st</sup> of June 2019. The Pillar Room, Rotunda Hospital, Dublin, Ireland

## **15- PUBLICATIONS**

### **Refereed Publications**

#### Articles

1. **Lambert JS**, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, Dolin R. Administration of 2'3'-dideoxyinosine (ddI) to patients with AIDS and ARC. *N Engl J Med*, 1990; 322:1333-1340.
2. Dolin R, **Lambert JS**, Morse GD, Reichman RC, Plank CS, Reid J, Knupp C, McLaren C, Pettinelli C. 2'3'-dideoxyinosine (ddi) in patients with AIDS and ARC. *Rev Infect Dis*, 1990; 12:540S-551S.
3. Cullen JB, Baram DA, Sherer DM, Woods JR Jr, **Lambert JS**, Reichman RC. Woman with AIDS presented for elective termination of pregnancy [letter]. *Am J Perinatol*, 1992; 9(4):313.
4. Drusano GL, Yuen GJ, **Lambert JS**, Seidlin M, Dolin R, Valentine FT. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection: a phase □ trial. *Ann Intern Med*, 1992; 116:562-566.

5. Drusano GL, Yuen GJ, Morse G, Cooley TP, Seidlin M, **Lambert JS**, Liebman HA, Valentine FT, Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2 $\beta$ , 3 $\beta$ -dideoxyinosine in phase I trials. *Antimicrob Agents Chemother*, 1992; 36(6):1280-3.
6. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, Schwartz DH, Agosti JM, Fermie HP, Stablein DM, Montefiore DC, **Lambert JS**, Hu SL, Lawrence D, Koff WC, and the AIDS Vaccine Clinical Trials Network. Vaccination of vaccine-naïve adults with human immunodeficiency virus type 1 gp160 recombinant vaccine virus in a blinded, controlled, randomized clinical trial. *J Infect Dis*, 1992; 166:244-252.
7. Kiebertz KD, Seidlin M, **Lambert JS**, Dolin R, Reichman RC, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. *J Acq Imm Def Syn*, 1992; 5:60-64.  
Schacter LP, Rozenzweig M, Beltangady M, Allan JD, Canetta R, Cooley TP, Dolin R, Kelley S, **Lambert JS**, Liebman HA, Messina M, Nicaise C, Seidlin M, Valentine F, Yarchoan R, Smaldone L. Effect of therapy with didanosine on hematologic parameters in patients with advanced HIV disease. *Blood*, 1992; 80:2969-2976.
8. Sperling RS, Stratton P, O'Sullivan MJ, Boyer P, Watts H, **Lambert JS**, Hammill H, Wilfert CW, Globel J, Minkoff H, Fox HE. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. *N Engl J Med*, 1992; 326:857-861.
9. Ukwu H, Graham BS, **Lambert JS**, Wright PF. Perinatal transmission of HIV-1 infection and immunization strategies for prevention. *Ob/Gyn*, 1992; 80:458-468
10. **Lambert JS**, Seidlin M, Valentine FT, Reichman RC, Dolin R. Didanosine: Long-term follow-up of patients in a phase I study. *Clin Infect Dis*, 1993; 16(Suppl 1):S40-S45.
11. **Lambert JS**, McNamara JG, Rodriguez EM, Fast PE. Summary of the perinatal intervention working group. *AIDS Res Hum Retroviruses*, 1993; (Suppl 1). 9:S53-S54.
12. **Lambert JS**, Stiehm ER. Passive immunity in the prevention of maternal-fetal transmission of human immunodeficiency virus infection. *Ann N Y Acad Sci*. 1993 Oct 29;693:186-93.
13. Plotnik L, DeVore R, **Lambert JS**. Barriers to care: Assessment of parental satisfaction in the paediatric HIV clinic. *Paediatric AIDS HIV Infect*, 1993; 4:130-137.
14. Reichman RC, Tejani N, **Lambert JS**, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. *Antiviral Res*, 1993; 20:267-77.
15. Hausler H, **Lambert JS**. Preparation for HIV vaccine trials: Ethical, behavioural, and social issues. *Pediatr AIDS and HIV Infection: Fetus to Adolescent*, 1994; 5:238-243.
16. **Lambert JS**, Slikker W Jr. Anti-HIV therapy and the placenta workshop. In: *Trophoblast Research: HIV, Perinatal Infections and Therapy: The Role of the Placenta*, Miller RK, Thiede HA (eds), 1994; 8:97-103.
17. **Lambert JS**, Stephens I, Christy C, Abramowicz JS, Woodin KA, HIV and syphilis: maternal and fetal considerations. *Pediatr AIDS and HIV Infect*, 1995.
18. **Lambert JS**. The prevention of maternal-fetal HIV-1 infection through passive antibody products (HIVIG) and active immunization (AIDS vaccines). *Pediatr AIDS HIV Infect*. 1995 Oct;6(5):300-2.
19. **Lambert JS**. Paediatric HIV infection. *Current Opinion in Paediatrics*, 1996; 8:606-614.
20. **Lambert JS**, Mofenson LM, Fletcher CV, Moye J Jr, Stiehm ER, Meyer WA 3rd, Nemo GJ, Mathieson BJ, Hirsch G, Sapan CV, Cummins LM, Jimenez E, O'Neill E, Kovacs A, Stek A. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their new-borns. Paediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. *J Infect Dis*. 1997 Feb;175(2):283-91
21. **Lambert JS**, HIV in women. (Book chapter) *Primary Care of Women*, Leppert and Howard (eds.), JB Lippencott (publishers), 1997.
22. **Lambert JS**, Viscidi R, Schwartz DH, Clayman B. Measurement of antibody to HIV-1 gp160 in mucosal specimens of asymptomatic seropositive volunteers immunized with parenterally administered ImmunoAG rgp 160 IIIB. *Clin Diagnostic Lab Immunol*, 1997.



23. **Lambert JS**, Watt C. Preventive and therapeutic HIV-1 vaccines, including those for the interruption of perinatal HIV-1 transmission. (Book chapter) *Medical Management of AIDS in Women*, Cotton and Watts (eds.), 1997.
24. MascolaJR, Louder MK, VanCott TC, Sapan CV, **Lambert JS**, Muenz LR, Bunow B, Birx DL, Robb ML. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. *J Virol*, 1997; 71(10): 7198-206.
25. Funkhouser AW, Katzman PJ, Sickel JZ, **Lambert JS**. CD30 (Ki-1)-positive anaplastic large cell lymphoma (ALCL) of T-cell lineage in a 14-month old infant with perinatally acquired HIV infection. *J Peds Hematol*, 1998; 20 (6): 556-559.
26. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, **Lambert JS**, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. *J Infect Dis*, 1998; 177 (2): 310-9.
27. **Lambert JS**. Tat toxoid: its potential role as an HIV vaccine [editorial]. *J Hum Virol*, 1998; 1(4): 249-50.
28. **Lambert JS**, Katz S, McNamara J. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. *J Acq Immun Defic Syndr Hum Retroviruses*, 1998; 19 (5): 451-461.
29. Nogueira SA, Caiuby MJ, Vasconcelos V, Halpern M, Gouveia C, Thorpe B, Ramparini C, **Lambert JS**. Paracoccidioidomycosis and tuberculosis in AIDS patients: Report of two cases. *Intl J Infect Dis*, 1998; 2 (3): 168-172.
30. **Lambert JS**, Moye Jr. J. Current issues in the immunoprophylaxis of vertical transmission of HIV. *Biodrugs*, 1999 January; 11 (1):31-41.
31. Stiehm ER, **Lambert JS**, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Moye J Jr, Glenn Fowler M, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA 3rd, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Paediatric AIDS Clinical Trials Group protocol 185. *J Infect Dis*. 1999 Mar;179(3):567-75
32. Mofenson LM, **Lambert JS**, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye Jr. J, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ. Risk factors for perinatal HIV transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. *N Engl JM*, 1999 Aug 5; 341 (6): 385-393.
33. Wright PF, **Lambert JS**, Gorse GJ, Hsieh R-H, McElrath, MJ, Weinhold, K, Wara, DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. *J Infect Dis*, 1999 Oct; 180 (4): 1080-1088.
34. Nogueira CAV, Nogueira CM, Nogueira SA, Abrao Jr IJ, Aradio AAC, Pereira GHS, Melle FJSG, **Lambert JS**, Edelman D, Constantine NJ, Coelho BSM. Posttransfusion-transmitted Hepatitis C virus infection in Brazilian patients - a prospective study. Postgraduate Course and Abstracts of the 34<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, 8-12 April, Naples, Italy. *Journal of Hepatology*. Suppl 1, Vol 30, 1999.
35. Stiehm ER, **Lambert JS**, Mofenson LM, Bethel JB, Whitehouse J, Nugent R, Moye Jr. J, Fowler MG, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. *J Infect Dis*, 1999; 179 (3): 567-575.

36. King Jr JC, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, **Lambert JS**, Belshe RB. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. *J Infect Dis* 2000 Feb;181(2):725-8.
37. Abreu T, Plaisance K, Rexroad V, Nogueira S, Oliveira RH, Evangelista LA, Rangel R, Silva IS, Knupp C, **Lambert JS**. Bioavailability of Once-and Twice Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children. *Antimicrob Agents Chemother* 2000 May; 44(5):1375-6
38. Chuachoowong R, Shaffer N, VanCott TC, Chaisilwattana P, Siriwasin W, Waranawat N, Vanprapa N, Young NL, Mastro TD, **Lambert JS**, Robb ML. Lack of Association between Human Immunodeficiency Virus Type-1 Antibody in Cervicovaginal Lavage Fluid and Plasma and Perinatal Transmission, Thailand. *JID* 2000;181 (June) 1957-1963. Epub 2000 May 18.
39. **Lambert JS**, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, Van Dyke R, Maupin R, Silio M, Fowler MG. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Paediatric AIDS Clinical Trials Group 185 Team. *AIDS*, 2000, July 7;14 (10):1389-99.
40. Watts DH, **Lambert JS**, Stiehm ER, Bethel J, Whitehouse J, Fowler MG, Read J. Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. *Am J Obstet Gynecol*. 2000 Jul;183(1):100-7.
41. **Lambert JS**, Gibb D. Paediatric HIV: Issues Regarding Antiretroviral Therapy. IAS International AIDS Society. No 17, Dec 1, 2000.
42. Watts H, **Lambert JS**, Stiehm ER, Bethel J, Whitehouse J, Fowler MG, Read J. Complications According to Mode of Delivery Among HIV-infected Women with CD4 Lymphocyte Counts of 500 or Less. *Am J Obstet Gynecol* 2000;183:100-7.
43. Ferreira E, Lucena S, Fonseca G, Barbosa TCM, Aquino RB, **Lambert JS**, Nogueira SA. Visceral leishmaniasis in a Brazilian child infected perinatally with human immunodeficiency virus. *The Paediatric Infectious Disease Journal*, Vol 20, no 2, pp 224-226, Feb 2001
44. Nogueira SA, Abreu T, Oliveira R, Araujo L, Costa T, Andrade M, Bronchini M, Psic FG, Machado E, Rodrigues K, Fernandes I, Mercadante R, Sapia C, **Lambert JS**. Successful prevention of HIV transmission from mother to infant: using a multidisciplinary team approach. *Brazilian Journal of Infectious Diseases* 2001, 5 (April) 78-87.
45. Nogueira SA, **Lambert JS**, Albuquerque AL, Rodrigues R, Reis S, Bornia R, Dias M, Barbosa R, Sztajnbock D, Constantine NT. Assessment of the rapid HIV test strategy during labour: a pilot study from Rio de Janeiro, Brazil. *Journal of the Institute of Human Virology*. 2001 Sept-Oct; 4 (5): 278-282.
46. Nogueira SA, Guedes AL, Wanke B, Rodrigues K, Capela S, Abreu T, **Lambert JS**: Osteomyelitis caused by *Paracoccidioides brasiliensis*: case report of a child living in a metropolitan area of Rio de Janeiro. *Journal of Tropical Pediatrics*, pp 311 - 315, Vol 47, October 2001.
47. Denise C N Sztajnbock, Suzie A. Nogueira, Raimunda Rodrigues, **Lambert JS**, Prevalencia da infeccao pelo Virus da Immunodeficiencia Humana, Virus da Hepatite B e Treponema pallidum em gestantes atendidas em maternidade publica do Rio de Janeiro.2001 (accepted)
48. Gazineo J, Trope B, Macieira J, May S, Coelho J, **Lambert JS**, Nogueira SA. Bacillary angiomatosis: description of 13 cases reported in five reference centers for AIDS treatment in Rio de Janeiro, Brazil. *Rev Inst Med. Trop S Paulo*, 2001; 43(1): 1-6.
49. **Lambert JS**, Redfield RR, Tramont ED. Therapeutic HIV vaccines: concept, current status and future directions. Book chapter, ed De Clerq, 2001.
50. **Lambert JS**, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. A phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1

- seronegative human subjects. *Vaccine* 19 (2001) 3033-3042.
51. Machado Elizabeth, **Lambert JS**, Watson D, Afonso A, Cubnha S, Nogueira S, Caride E, et al. Analise gGenotipica em Crianças HIV-1 + Em uso de Terapia Antiretroviral dupla ou Tripla no Rio de Janeiro: Resistencia ou Baixa Asesao. *BJID* 2001; 5 (Supp 2), page S32.
  52. Madhivanan P, Mothi SN, Kumarasamy N, Vepthomi T, **Lambert JS**, Solomon S Regression of Attained Milestones in an HIV infected infant. *Indian J Paeds*. Vol 68 (10): 991-993, 2001.
  53. Madhivanan P, Kumarasami N, Solomon S, **Lambert JS et al**. MTCT of HIV: a prevention program in a tertiary care HIV centre in South India. Accepted *Ind J Peds*. 2001
  54. Villela Nogueira C, Nogueira S A, Nogueira CN, Coelho HS, Ketema F, Edelman DC, **Lambert JS & Constantine NT**: The incidence of GB virus C/Hepatitis G virus infection in Brazilian patients who received blood transfusion during cardiac surgery. *J Med Virol*. 2001; 63 (3): 237- 41.
  55. Suzie A Nogueira, Rosalie Branco Correa, Marcelo Holanda, Marcelo X, Fernanda Queiroz, **Lambert JS**. Co-infection of *Strongyloides stercoralis* and HIV-1: a case series of hospital-based patients from Rio de Janeiro, Brazil.. (Submitted *J Retrovirology*)
  56. Nogueira CA, Edelman DC, Nogueira CM, Nogueira SA, Coelho HS, Abrahao LJ, Vanderbogh B, **Lambert JS**, Constantine NT. Hepatitis C virus transfusion-transmitted infection in Brazil cardiac surgery patients. *Clin Lab* 2002; 48(9-10): 529-33.
  57. Suttmoller F, Therezinha LP, De Souza CT, **Lambert JS**. Human Immunodeficiency Virus incidence and Risk Behavior in the 'Projecto Rio' results of the first five years of the Rio de Janeiro Open Cohort of Homo-Bisexual Men 1994-1998. *IJID Intern. J Inf. Dis* 2002 Dec; 6(4): 259-65.
  58. Nogueira SA, Guedes AL, Machado ES, Matos JA, Costa TP, Corte EM, **Lambert JS** Toxoplasma encephalitis in an HIV infected pregnant woman with successful outcome for both mother and child. *Braz J Infect Dis*. 2002 Aug; 6 (4): 201-5. Epub 2003 Apr 1.
  59. Watts DH, **Lambert JL**, Stiehm ER, Harris DR, Bethel J, Mofenson LM, Meyer WA, Mathieson B, Fowler MG, Nemo G; and the PACTG 185 team. Progression of HIV disease among women following delivery. *J Acquir Immune Defic Syndr*. 2003 Aug 15; 33 (5); 585-93
  60. Madhivanan P, Mothi SN, Kuramasami N, Yepthomi T, Venkatesan C, **Lambert JS**, Solomon S, Clinical manifestations of HIV in children at a HIV care center in Chennai, India. *Indian Journal of Paediatrics* 2003, August: 70(8):615-620.
  61. **Lambert JS**, Nogueira SA, Abreu T, Machado ES et al. A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil. *Sex Transm Infect*. 2003 Dec; 79 (6) 448-524.
  62. **Lambert JS**, Harris DR, Stiehm ER, Moye J Jr, Fowler MG, Meyer WA, Bethel J, Mofenson LM. Performance Characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. *J Acquir Immune Defic Syndr*. 2003 Dec 15; 34(5):512-9.
  63. Machado ES, **Lambert JS**, Afonso et al. Alternative age and viral load related routes of nelfinavir resistance in HIV-1 infected children under highly active antiretroviral therapy. *Pediatr Infectious Dis Journal*. 2004 Nov; 23(11):1057-9.
  64. Machado ES, **Lambert JS**, Afonso O et al. Overview of genotypic and clinical profiles of human immunodeficiency virus type 1 infected children in Rio de Janeiro, Brazil. *Ann Acad Bras Cienc*. 2004 Dec; 76(4): 727-41. Epub 2004 Nov 16.
  65. Machado ES, **Lambert JS**, Watson et al. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. *J Clinical Virology* 30, 2004 May; 30 (1): 24-31. PMID: 15072750
  66. **Lambert JS**, Moye J, Pleagar SF, Stiehm ER, Bethel J, Mofenson L, Mathieson B, Kagan J, Rosenblatt H, Paxton H, Suter H, Landay A. Association of selected phenotypic markers of activation and differentiation with immunodeficiency virus transmission and infant infection. *Clin Diagn Lab Immunol*. 2005 May; 12(5): 622-31.
  67. **Lambert JS**. HIV vaccines in infants and children. *Paediatr Drugs*. 2005 Dec; 7 (5):267-76. Review.

68. Chew N, **Lambert JS**. Meeting report of the 10<sup>th</sup> European AIDS Conference (EACS) 17-20 November 2005. *J HIV Therapy: Current Trends* Vol 10, 4, Dec 2005, 79-80.
69. **Lambert JS**, Clapson M. In search of a paediatric HIV vaccine: scientific and ethical issues. *HIV Nursing* vol 5, 4, Winter 2005, 9-12.
70. Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS, Hawkins E, Bouquin P, Estep SG, Tomaras GD, Vincent CA, Rathore M, Melvin AJ, Gurunathan S, **Lambert, JS**. Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1-Infected Women. *JID* 2005; 192:2129-33.
71. McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J, Read JS, Douglas SD, Develle J, Gurwith M, Gurunathan S, **Lambert JS**, HIV-1 vaccine induced immune responses in new-borns of HIV-1 infected mothers. *AIDS*, 2006 Jul13; 20(11)1481-9.
72. McMillan HM, O'Carroll H, **Lambert JS**, Grundy KB, O'Reilly M, Lennon B, Collins C, Walsh TA,, Geary MP, Cafferkey MK. Screening for Chlamydia trachomatis in asymptomatic women attending outpatient clinics in a large maternity hospital in Dublin, Ireland. *Sex Transm Infect.* 2006 Dec; 82(6):503-5. Epub 2006 Jul 19.
73. McDonald C, **Lambert JS**, Nayagam D, Welz T, Poulton M, Aleksin D, Welch J. Why are children still being infected with HIV? Experience in the prevention of mother to child transmission of HIV in South London. *Sex. Transm. Inf.* 2007; 83: 59-63. Published online 27 Sept 2006; doi: 10.1136/sti.2006.021535.
74. Samuel M, Aderogba K, Dutt N, **Lambert JS**, Taylor C. A hat trick of ulcerating pathogens in a single genital lesion. *International Journal of STDs and AIDS* 2007 Jan; 18 (1): 65-6.
75. Scott CJ, **Lambert JS**, Taylor CB, Poulton MB. Invasive *Aspergillus fumigatus* associated with liver and bone involvement in a patient with AIDS. *Int J Infect Dis.* 2007 Nov: 11 (6):550-3. Epub 2007 Mar 23.
76. **Lambert JS**. Long-term follow-up of a quadrivalent HPV vaccine. *Expert Rev Vaccines.* 2007 Apr; 6 (2): 141-5
77. **Lambert JS**, Machado ES, Watson DC, Sill Am, Lim JK, Charurat M, Chunha SM, Afonso AO, Oliveria RH, Tanuri A, DeVico AL. Production of the HIV-suppressive chemokines CCL3/MIP-1 alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children. *Pediatr Infect Dis J.* 2007 Oct; 26(10): 935-44.
78. Gallagher D, **Lambert JS**, Keran J, Sheehan G, Mahon N, Mallon P. MS 53262, Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia – two case reports. *Clin Infect Dis.* 2008 Aug 1; 47(3):e36-8.
79. McMenahin M, Jackson A, **Lambert JS**, Hall W, Butler K, Coulter-Smith S, McAuliffe F. Obstetric management of hepatitis C positive mothers: analysis of vertical transmission in 559 mother-infant pairs. *Am J Obstet Gynecol* 2008; 199: 315.e1-315.e1-5.doi: 10.1016/j.ajog.2008.05.021 PMID: 18771997
80. Machado E, Hofer C, Nogueira S, Costa T, Oliveira R, Abreu T, Farias I FA, Mercandante R TS, Garcia MFL, Neves R, Costa V, **Lambert JS**. Pregnancy outcome in HIV-1 infected women receiving combination therapy prior versus after conception. *STI*, Apr 2009, ; 85(2):82-7 e pub 2008 Nov 5- doi: 10.1136/sti.2008.032300
81. Cotter A, **Lambert JS**. Retrospective analysis of female patients screened at Mater Misericordiae University Hospital, Dublin, Sexually Transmitted Infection Clinic over a 12-month period. Submitted to *Irish Medical Journal (IMJ)*, 2008.
82. Cotter A, Treacy A, O'Keane C, Mulligan N, **Lambert JS**. Cutaneous T-cell lymphoma presenting as a ten-month history of unilateral facial swelling. *IrMed J.* 2008 May;101(5):151-2. PMID 18624265
83. Roe B, Coughlan S, Dean J, **Lambert JS**, Keating S, Norris S, Bergin C, Hall W. Phenotypic & Functional Characterisation of Lymphocytes in HCV/HIV Co-infected Patients. *Viral Immunology* Volume 22, Number 1, pp 39-47, 2009.
84. De Gascun C, Brannigan E, McSweeney F, Duffy M, Keegan DJ, Hall W, **Lambert JS**.

Management of Ganciclovir resistant cytomegalovirus retinitis in human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Submitted, 2009.

85. FM. Fusco, S Schilling, V Puro, HR. Brodt, P. Follin, B. Jarhall, B. Bannister, HC. Maltezoou, G. Thompson, P. Brouqui, G. Ippolito, EURONHID Study Group. Collaborators: O. Adrami, M. Borg, R. Gottschalk, R. Hemmer, A. Horban, M. Kojouharova, C Peronne, **Lambert JS**, H. Siikamaki, P. Skinhoj, F. Strle, A. Trilla, N Vetter. EuroNHID checklists for the assessment of high-level isolation units and referral centres for highly infectious diseases: results from the pilot phase of a European survey. *Clin Microbiol Infect.* August 2009;15 (8): 711-9. Epub May 28<sup>th</sup>, 2009.
86. Cotter A, Downes MR, O'Keane C, O'Gorman P, **Lambert JS**. Multicentric Castleman's disease & HIV infection. *Ir Med J.* Oct 2009; 102(9):294-5.
87. Cotter A, **Lambert JS**, O'Gorman P. Multicentric Castleman's disease and HIV infection. *IR Med J* 2009 Oct;102 (9);294-5. PMID 19902650
88. Coulter-Smith S, **Lambert JS**, Butler K; Brennan M, Cafferkey M. HIV testing and treatment in the antenatal care setting: An Irish Maternity Hospital Experience. *IMJ*, 2010 Jan;103(1):14-7.
89. Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, **Lambert JS**, Sheehan GJ, Kenny D, Mallon PW. Platelet function and HIV: a case control study. *AIDS* 2010 Mar 13, 24(5):649-57. PMID 20177361
90. Caswell RJ, Phillips D, Chaponda M., Khoo SH, Taylor GP, Ghanem M, Poulton M, Welch J, Gibbons S, Jackson V. **Lambert JS**. The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. *Accepted Int J STD AIDS*, 2010;00: 1-4 Q 3.
91. Kearney F, Moore AR, Donegan CF, **Lambert JS**. The ageing of HIV: implications for geriatric medicine. *Age Ageing.* 2010 Sep;39(5):536-41. Epub 2010 Aug 4. PMID: 20685813
92. Stellbrink HJ., Orkin C., Arribas JR., Compson J, Gerstoft J, Winjgaerden EV, Lazzarin A, Rizzardini G, Sprenger H, **Lambert JS**, Sture G, Leather D, Hughes S, Zucchi P, Pearce H. Comparison of Changes in Bone Density and Turnover with Once Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine in HIV1 Infected Adults: 48 week results from the Assert Study, *HIV/AIDS, CID* 2010 Oct 15:51 doi: 10.1086/656417 PMID: 20828304
93. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, Keaveney M., **Lambert JS**. McCormick A, McKiernan S, Moloney J, Perry N, Cullen W. Barriers to and Facilitators of Hepatitis C Testing, Management, and Treatment Among Current and Former Injecting Drug Users: A Qualitative Exploration, *AIDS Patient Care and STDs*, Volume 24, Number 12, 2010.
94. PENPACT-1 (PENTA 9/PACTG 390) Study Team, A. Babiker, H. Castro nee Green H, A. Compagnucci, S. Fiscus, C. Giaquinto, DM. Gibb, L. Harper, L. Harrison, M. Hughes, R Mc Kinney, A. Melvin, L. Mofenson, Y. Saidi, ME. Smith, G. Tudor-Williams, AS. Walker. Collaborators. **Lambert JS** et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. *Lancet Infect Dis.* 2011 Apr;11(4): 273-83. Epub 2011 Jan 31.
95. Cotter AG, Satchell CS, O'Halloran JA, Feeney ER, Sabin CA, **Lambert JS**, Sheehan G, Mallon PWG. High density lipoprotein cholesterol and 10-year cardiovascular risk in HIV –infected patients. *AIDS* 2011 Mar 27;25(6):867-9. PMID 21330909
96. **Lambert JS**, I.J. Else, V. Jackson, J. Breiden, S. Gibbons, L. Dickinson, D.J. Back, M. Brennan, E.O. Connor, N. Boyle, C.Fleming, S. Coulter-Smith, S.H. Khoo. Therapeutic Drug Monitoring of Lopinavir/Ritonavir in pregnancy. *HIV Medicine* (2011), 12, 166-173.
97. Caswell RJ, Phillips D, Chaponda M., Khoo SH, Taylor GP, Ghanem M, Poulton M, Welch J, Gibbons S, Jackson V, **Lambert JS**.. Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. *International Journal of STD & AIDS* 2011; 22: 11-14.
98. O'Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, Hall WW, **Lambert JS**. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. *J Clin Virol.* 2011

- Oct;52(2):151-4. doi: 10.1016/j.jev.2011.06.020. Epub 2011 Jul 28.PMID: 21802353
99. Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, Feeney ER, **Lambert JS**, Sheehan GJ, Kenny D, Mallon PW. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. *J Infect Dis.* 2011 Oct 15; 204(8): 1202-10.doi: 10.1093/infdis/jir509.PMID: 21917893
  100. Fusco FM, Schilling S, De Iaco G, Brodt HR, Brouqui P, Maltezou HC, Bannister B, Gottschalk R, Thomson G, Puro V, Ippolito G; **Lambert JS**,EuroNHID Working Group.Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. *BMC Infect Dis.* 2012 Jan 28;12:27. doi: 10.1186/1471-2334-12-27.PMID: 22284435
  101. Thiberville SD, Schilling S, De Iaco G, Fusco FM, Thomson G, Maltezou HC, Gottschalk R, Brodt RH, Bannister B, Puro V, Ippolito G, Brouqui P; **Lambert JS**, EuroNHID Working Group.Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys.*BMC Res Notes.* 2012 Sep 25;5:527. doi: 10.1186/1756-0500-5-527.
  102. Else L, Jackson V, Brennan M, Breiden J, Lawless M, Coulter Smith S, Back D, Khoo S, **Lambert JS**. Therapeutic drug monitoring (TDM) of atazanavir in pregnancy. *J Int AIDS Soc.* 2012 Nov 11; 15(6): 18330. doi: 10.7448/IAS.15.6.18330.
  103. O'Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, Hall WW, **Lambert JS**. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. *Journal of Clinical Virology* 52 (2011) 151-154. doi: 10.1016/j.jev.2011.06.020. Epub 2012 Nov 29.
  104. Calamai A, Howard R, Kelly R and **Lambert JS**. Impact on practice of a British Association for Sexual Health and HIV Sexually Transmitted Infections Foundation course: an audit of the first four years in Ireland DOI: 10.1177/0956462412472304. *International Journal of STD & AIDS* 2012; 0: 1–5
  105. Feeney ER, Mc Auley N, O'Halloran JA, Rock C, Low J, Satchell CS, **Lambert JS**, Sheehan GJ, Mallon PW. The Expression of Cholesterol Metabolism Genes in Monocytes from HIV-Infected Subjects Suggests Intracellular Cholesterol Accumulation. *J Infect Dis.* 2013 Feb;207(4):628-37. doi 10.1093/infdis/jis723. Epub 2012 Nov 29.
  106. Calamai A, Howard R, Kelly R, **Lambert JS**. Impact on practice of a British Association for Sexual Health and HIV Sexually Transmitted Infections Foundation (STIF) course: an audit of the first four years in Ireland. *Int J STD AIDS.* 2013 Feb;24(2):144-8. doi: 10.1177/0956462412472304. Epub 2013 May 6
  107. **Lambert JS**, Jackson V, Coulter-Smith S, Brennan M, Geary M, Kelleher TB, O'Reilly M, Grundy K, Sammon N, Cafferkey M. Universal Antenatal Screening for Hepatitis C. *Ir Med J.* 2013 May;106(5):136-9
  108. Cotter AG, Brown A, Sheehan G, **Lambert JS**, Sabin CA, Mallon PWG. Predictors of Change in Bilirubin levels over 12 weeks of treatment with Atazanir. *AIDS Res Ther* 2013 May 16;10(1):13 PMID 23680529
  109. Cotter AG, Brown A, Sheehan G, **Lambert JS**, Sabin CA, Mallon PW. Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir. *AIDS Res Ther.* 2013 May 16;10(1):13. doi: 10.1186/1742-6405-10-13.PMID: 23680529
  110. Klimas J, Field CA, Anderson R, Barry J, Bedford D, Bourke M, Bury G, Corrigan G, Doyle J, Flanagan J, Gallagher H, Geoghegan N, Harkin K, Keenan E, **Lambert JS**, McAuliffe R, McCann ME, McCormick A, O'Driscoll D, O'Gara C, Perry N, Smyth BP, Weldon F, Cullen W. Problem Alcohol use among problem drug users : Development of Clinical Guidelines for General Practice. *Irish Journal of Medical Science*, submitted15<sup>th</sup>May, 2013.
  111. Low J, Crowley D, Nicholls M, Cullen W, Flanagan J, Glover N, Jackson V, **Lambert JS**. Attitudes Towards and Knowledge of Hepatitis C among Patients Attending a Community Based Specialist Drug Treatment Service. Submitted *BMC Research notes.* July 2013.
  112. Ni Chroinin,D, **Lambert JS**. Sudden Headache, third nerve palsy and visual deficit: thinking outside the subarachnoid haemorrhage box. *Age and Ageing* 2013; 42: 810-812doi:

- 10.1093/ageing/af088. August 1,2013
113. Sadlier CM, Brown A, **Lambert JS**, Sheehan G, Mallon PW. Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic. *AIDS Res Ther.* 2013 Sep 8;10(1):23.
  114. Monteith C, Ainle FN, Cooley S, **Lambert JS**, Kelleher B, Jackson V, Eogan M. Hepatitis C virus-associated thrombocytopenia in pregnancy: impact upon multidisciplinary care provision. *J Perinat Med.* 2013 Sep 4:1-4. doi: 10.1515/jpm-2013-0080.
  115. Tinago W, O'Halloran JA, O'Halloran RM, Macken A, **Lambert JS**, Sheehan GJ, Mallon PWG. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. *HIV Med.* 2013 Nov 12. doi: 10.1111/hiv.12107
  116. **Lambert JS**, Avramovic G, Jackson V, Sammon N, Lally S, Campbell FJ. Investigation into the Reasons for Maternal Default from HIV Care Postpartum. A 3-Year Retrospective Review. *AIDS PATIENT CARE and STDs*, Volume 28, Number 1, 2014, DOI: 10.1089/apc.2013.0267
  117. Tinago W, Coghlan E, Macken A; McAndrews A, Doak B; **Lambert JS**; Sheehan GJ; Mallon PWG. Clinical, immunological and treatment-related predictors of normalisation of CD4+/CD8+ T-cell ratio: effect of naïve and memory T-cell subsets. Submitted PLOS ONE EMID:2915ef130169d74c
  118. Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S and **Lambert JS**. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy DOI: 10.1111/hiv.12164 *HIV Medicine* (2014)
  119. Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, **Lambert JS**, Sheehan GJ, Mallon PWG, on behalf of the Mater Immunology Study Group. Clinical, Immunological and Treatment-Related Factors Associated with Normalised CD4+/CD8+ T-Cell Ratio: Effect of Naïve and Memory T-Cell Subsets. *Plos One*, May 2014, Volume 9, Issue 5, e97011
  120. Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S, **Lambert JS**. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. *HIV Med.* 2014 Nov;15(10):604-10. doi: 10.1111/hiv.12164. Epub 2014 May 14.
  121. Colbers A, Hawkins D, Tenorio H, Van der Ende M, Gingelmaier A, **Lambert JS** et al. D Burger. Atazanavir Exposure is Effective during Pregnancy, Regardless of Tenofovir Use. *Antivir Ther.* 2014 Jul 3. doi: 10.3851/IMP2820
  122. Jackson V, Ferguson W, Kelleher TB, Lawless M, Eogan M, Nusgen U, Coughlan S, Connell J, **Lambert JS**. Lamivudine treatment and outcome in pregnant women with high Hepatitis B viral loads. *European Journal of Clinical Microbiology & Infectious Diseases*, November 2014.
  123. Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S, **Lambert JS**. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. *HIV Med.* 2014 Nov;15(10):604-10. doi: 10.1111/hiv.12164. Epub 2014 May 14.
  124. Waqas S, O'Connor M, Levey C, Mallon P, Sheehan G, Patel A, Avramovic G, **Lambert JS**. Real life experience of Dolutegravir (DTG) in HIV infected treatment naïve patients from a tertiary care university hospital in Ireland. *International journal of STD & AIDS* 03 July 2016 Manuscript ID – 1 JSA- 16- 2016
  125. Moore R, Adler H, Jackson V, Lawless M, Byrne M, Eoghan M, **Lambert JS**, Impaired glucose metabolism in HIV- infected pregnant: a retrospective analysis, *International journal of STD & AIDS* 2016, Vol 27 (7) 581- 585
  126. Gray E, O'Leary A, Stewart S, Bergin C, Cannon M, Courtney G, Crosbie O, De Gascun CF, Fanning LJ, Feeney E, Houlihan DD, Kelleher B, **Lambert JS**, Lee J, Mallon P, McConkey S, McCormick A, McKiernan S, McNally C, Murray F, Sheehan G, Norris S; Irish Hepatitis C Outcomes and Research Network (ICORN). High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme. *J Hepatol.* 2016 Aug;65(2):446-8. doi: 10.1016/j.jhep.2016.03.022. Epub 2016 Apr 27. No abstract available.

127. McCombe, G., Leahy, D., Klimas, J., **Lambert JS**, Cullen, W., & Henihan, A. M. (2016). Commentary on Zeremski et al. (2016): Improvements in HCV-related Knowledge among Substance Users on Opioid Agonist Therapy after an Educational Intervention. *Journal of Addiction Medicine*, 10(5), 363-364.
128. Henihan, A.M., McCombe, G., Klimas, J., Swan, D., Anderson, R., Bury, G., Dunne, C., Keenan, E, **Lambert JS**, Meagher, D., O’Gorman, C., O’Toole, T., Saunders, J., Smyth, B.P., Shorter, G., Kaner, E., Cullen, W. (2016) Feasibility of Alcohol Screening among Patients receiving Opioid Treatment in Primary Care. *BMC Family Practice*. DOI: 10.1186/s12875-016-0548-2
129. McCombe, G., Henihan, A.M., Klimas, J., Swan, D., Leahy, D., Anderson, R., Bury, G., Dunne, C., Keenan, E., **Lambert JS**, Meagher, D., O’Gorman, C., O’Toole, T., Saunders, J., Smyth, B.P., Kaner, E., Cullen, W., (2016). Enhancing alcohol screening and brief intervention among people receiving opioid agonist treatment: qualitative study in primary care. *Drugs and Alcohol Today*, 16(4)
130. Linder V, Goldswain C, Adler H, Carty C, Harper K, Jackson V, **Lambert JS**, Boon G. Lamivudine Monotherapy: Experience of Medium-term Outcomes in HIV-infected Children Unable to Adhere to Triple Therapy. *Pediatr Infect Dis J*. 2016 Jul;35(7):e199-205. doi: 10.1097/INF.0000000000001156.
131. McCombe G, Leahy D, Klimas J, **Lambert JS**, Cullen W, Henihan AM. Commentary on Zeremski et al. (2016): Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. *J Addict Med*. 2016 Sep-Oct;10(5):363-4. doi: 10.1097/ADM.0000000000000244. No abstract available. PMID: 27685682
132. Gray E, O’Leary A, Bergin C, Cannon M, Courtney G, Crosbie O, De Gascun CF, Fanning LJ, Feeney E, Houlihan DD, Kelleher B, **Lambert JS**, Lee J, Mallon P, McConkey S, McCormick A, McKiernan S, McNally C, Murray F, Sheehan G, Stewart S, Walsh C, Norris S; Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. *Irish Hepatitis C Outcomes and Research Network (ICORN).Expert Rev Gastroenterol Hepatol*. 2017 Jun;11(6):593-601. doi: 10.1080/17474124.2017.1292850. Epub 2017 Feb 22. PMID: 28276815
133. McGettrick P, Ghavami-Kia B, Tinago W, Macken A, O’Halloran J, **Lambert JS**, Sheehan G, Mallon PWG. The HIV Care Cascade and sub-analysis of those linked to but not retained in care: the experience from a tertiary HIV referral service in Dublin Ireland. *IV Clin Trials*. 2017 May;18(3):93-99. doi: 10.1080/15284336.2017.1298317. Epub 2017 Mar 14.
134. Crowley D, Cullen W, Laird E, **Lambert JS**, Mc Hugh T, Murphy C, Van Hout MC Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic. *J Transl Int Med*. 2017 Jun 30;5(2):112-119. doi: 10.1515/jtim-2017-0017.eCollection 2017 Jun.
135. Adeniyi, VO. Ajayi A, Selanto-Chairman N. Ter Goon D. Boon G, Fuentes Y, Hofmeyr G, Avramovic G, Carty C. **Lambert JS**. Demographic, Clinical and Behavioural, Determinants of HIV Serostatus Non-disclosure to Sex Partners among HIV-Infected Pregnant Women in the Eastern Cape, South Africa. PONE-D-17-05551R1 - [EMID:bc6ff1673601f1f4]
136. O’Higgins AC, Jackson V, Lawless M, Le Blanc D, Connolly G, Drew R, Eogan M, Lambert JS Screening for asymptomatic urogenital Chlamydia trachomatis infection at a large Dublin maternity hospital: results of a pilot study. *Ir J Med Sci*. 2017 May;186(2):393-397. doi: 10.1007/s11845-016-1429-3. Epub 2016 Mar 11 PMID: 26969456
137. McCombe G, Almaazmi B, **Lambert J**, Avramovic G, Murphy C, O’Connor M, Perry N, Cullen W: Integrating primary and secondary care to optimise hepatitis C treatment: Development and evaluation of a multidisciplinary educational ‘Masterclass’ series. *International Journal of Integrated Care* 2017, 17(5).
138. **Lambert J**, Murphy C, Menezes D, Cullen W, McHugh T, O’Carroll A: Hepcheck Dublin: Homeless, Hep C & Competing Priorities. *International Journal of Integrated Care* 2017, 17(5).



- Lambert J**, Avramovic G, McCombe G, Murphy C, Swan D, O'Connor E, Cullen W: HEP CARE EUROPE: Bridging the gap in the treatment of Hepatitis C. *International Journal of Integrated Care* 2017, 17(5).
139. **Lambert J**, Sociocultural and Behavioural Determinants of HIV Serostatus Non-disclosure to Sex Partners among HIV-Infected Pregnant Women in the Eastern Cape, South Africa PONE-D-17-05551
  140. Adeniyi OV, Ajayi AI, Selanto-Chairman N, Goon DT, Boon G, Fuentes YO, Hofmeyr GJ, Avramovic G, Carty C, **Lambert J**; East London Prospective Cohort Study (ELPCS) Group. Demographic, clinical and behavioural determinants of HIV serostatus non-disclosure to sex partners among HIV-infected pregnant women in the Eastern Cape, South Africa. *PLoS One*. 2017 Aug 24;12(8):e0181730. doi: 10.1371/journal.pone.0181730. eCollection 2017.
  141. Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, **Lambert J**, van der Ende M, Moltó J, Burger D; Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. *Clin Infect Dis*. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534.
  142. Adeniyi V; Idowu Ajayi A.; Mayowa G Moyaki; Goon D; Avramovic G; **Lambert J**. High rate of unplanned pregnancy in the context of integrated family planning and HIV care services in South Africa November 2017 BHSR-D-17-01713
  143. Adeniyi OV, Ajayi AI, Selanto-Chairman N, Goon DT, Boon G, Fuentes YO, Hofmeyr GJ, Avramovic G, Carty C, **Lambert J**; East London Prospective Cohort Study (ELPCS) Group. Demographic, clinical and behavioural determinants of HIV serostatus non-disclosure to sex partners among HIV-infected pregnant women in the Eastern Cape, South Africa. *PLoS One*. 2017 Aug 24;12(8):e0181730. doi: 10.1371/journal.pone.0181730. eCollection 2017.
  144. Adeniyi O; Idowu Ajayi A.; Mayowa G Moyaki; Goon D; Avramovic G; **Lambert J**. High rate of unplanned pregnancy in the context of integrated family planning and HIV care services in South Africa November 2017 BHSR-D-17-01713
  145. Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, Vickerman P, **Lambert JS**. Hepcare Europe - Bridging the gap in the treatment of hepatitis C: study protocol. *Expert Rev Gastroenterol Hepatol*. Vol 12 Issue 3. 2018 Mar;12(3):303-314. doi: 0.1080/17474124.2018.1424541. Epub 2018 Jan 16. PMID: 29300496
  146. Adeniyi OV, Ajayi AI, Ter Goon D, Owolabi EO, Eboh A, **Lambert J**. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. *BMC Infect Dis*. 2018 Apr 13;18(1):175. doi: 10.1186/s12879-018-3087-8.
  147. McCombe G, Swan D, O'Connor E, Avramovic G, Vickerman P, Ward Z, Surey J, Macías J, **Lambert JS**, Cullen W. Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. *JMIR Res Protoc*. 2018 Jun 4;7(6):e149. doi: 10.2196/resprot.9043. PMID: 29866641 [PubMed]
  148. Adeniyi OV, Idowu Ajayi A, Ter Goon D, Owolabi EO, Eboh A, **Lambert JS**, Factors Affecting Adherence to Anti-Retroviral Therapy among Pregnant Women in the Eastern Cape, South Africa, *BMC Infect Dis*. 2018 Apr 13;18(1):175. doi: 10.1186/s12879-018-3087-8.
  149. Avramovic G; **Lambert JS**, Uptake of Isoniazid prevention therapy and mantoux test among HIV-infected pregnant women in the Eastern Cape, South, *BMC Infectious Diseases* INFD-D-18-01229
  150. Adeniyi Oladele V, Idowu Ajayi A, Ph.D; Issah M, Omolara, Owolabi E, Ter Goon D, Avramovic G, **Lambert JS**, Beyond Clinicians' Recommendations: Understanding influences on infant feeding choices of HIV-infected peripartum women in the Eastern Cape, South Africa *BMC Infectious Diseases* ,IBFJ-D-18-00066
  151. McCombe G, Swan D, O'Connor E, Avramovic G, Vickerman P, Ward Z, Surey J, Macías J, **Lambert JS**, Cullen W. Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. *JMIR Res Protoc*. 2018 Jun 4;7(6):e149. doi: 10.2196/resprot.9043. PMID: 29866641 [PubMed]

152. McCombe G, Swan D, O'Connor E, Avramovic G, Vickerman P, Ward Z, Surey J, Macías J, **Lambert JS**, Cullen W. Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. *JMIR Res Protoc*. 2018 Jun 4;7(6):e149. doi: 10.2196/resprot.9043. PMID: 29866641 [PubMed]
153. O'Meara P, Swan D, O'Connor E, McCombe G, Murphy C, **Lambert JS**, Avramovic G, Cullen W Integrating Hepatitis C Care for at-risk groups: Findings from a Service Innovation Project in Primary Care., UCD School of Medicine Summer Students Research Awards 2018 *Irish Journal of Medical Science (1971 -)* (2018) 187 (Suppl 1 ):S325–S354 <https://doi.org/10.1007/s11845-018-1941-8>
154. Hoong Tan C, McCombe G, McHugh T, Avramovic G, Cullen **Lambert JS** ,Hepatitis C Screening: A Scoping Review and Data Analysis., School of Medicine Summer Students Research Awards 2018 UCD School of Medicine, University College Dublin, Belfield, Dublin 4. *Irish Journal of Medical Science (1971 -)* (2018) 187 (Suppl 1 ):S325–S354 <https://doi.org/10.1007/s11845-018-1941-8>.
155. Murtagh R, Swan D, O'Connor E, McCombe G, **Lambert JS**, Avramovic G, Cullen W. Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study. *Interact J Med Res*. 2018 Dec 19;7(2):e10313. doi: 10.2196/10313. PMID: 30567692 [PubMed]
156. Crowley D, Van Hout MC, **Lambert JS**, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective. *Harm Reduct J*. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z. PMID: 30538000 [PubMed - in process]
157. Crowley D, Van Hout MC, Murphy C, Kelly E, **Lambert JS**, Cullen W.Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration. *Health Justice*. 2018 Dec 19;6(1):23. doi: 10.1186/s40352-018-0081-6.
158. **Lambert JS**, Murtagh R, Menezes D, O'Carroll A, Murphy C, Cullen W, McHugh T, Avramovic G, Tinago W, Van Hout MC, 'HepCheck Dublin': An Intensified Hepatitis C Screening Programme in a Homeless Population Demonstrates the Need for Alternative Models of Care, *BMC Infectious Diseases* DOI: 10.1186/s12879-019-3748-2 (Accepted Jan 2019)
159. Adeniyi OV, Ajayi AI, Issah M, Owolabi EO, Goon DT, Avramovic G, **Lambert JS**, Beyond health providers' recommendations: understanding influences on infant feeding choices women with HIV in the Eastern Cape, South Africa. *International Breastfeeding Journal* 2019 Jan 31;14:7. doi: 10.1186/s13006-019-0201-5. eCollection 2019.
160. Adeniyi Oladele V, Idowu Ajayi A, Ph.D; Issah M, Omolara, Owolabi E, Ter Goon D, Avramovic G, **Lambert JS**, Beyond Clinicians' Recommendations: Understanding influences on infant feeding choices of HIV-infected peripartum women in the Eastern Cape, South Africa *BMC Infectious Diseases* ,IBFJ-D-18-00066 *International Breastfeeding Journal* (Jan 2019) 14:7<https://doi.org/10.1186/s13006-019-0201-5>
161. Kuan, K, Else, L, Khoo, S, Jackson V, Patel Anjali, Lawler M, McDonald, G, Le Blanc D, Avramovic, Avramovic G, Redmond N, Murtagh, R, **Lambert JS**, Therapeutic drug monitoring of darunavir/ritonavir in pregnancy, *International Medical Press (AVT-18-SC-4459)* doi: 10.3851/IMP3291 *International Medical Press: Antiviral Therapy IMP3291* Published February 2019
162. McGinty T, Cotter AG, Sabin CA, Macken A, Kavanagh E, Compston J, Sheehan G, **Lambert J**, Mallon PWG. HIV UPBEAT (Understanding the Pathology of Bone Diseases in HIV-infected Subjects) Study Group Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. *PLoS One*. 2019 Mar 21;14(3):e0213440. doi: 10.1371/journal.pone.0213440. eCollection 2019.
163. **Lambert JS**, Cook MJ, Healy JE, Murtagh R, Avramovic G, Lee SH. Metagenomic 16S rRNA gene sequencing survey of *Borrelia* species in Irish samples of *Ixodes ricinus* ticks. *PLoS One*. 2019 Apr 15;14(4):e0209881. doi: 10.1371/journal.pone.0209881. eCollection 2019.

164. Murtagh R, Else LJ, Kuan KB, Khoo SH, Jackson V, Patel A, Lawler , McDonald G, Le Blanc D, Avramovic G, Redmond N, **Lambert JS**. Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. *Antivir Ther.* 2019;24(3):229-233. doi: 10.3851/IMP3291
165. Crowley D, Cullen W, **Lambert JS**, Hout MCV Hepatitis c treatment and prevention in people who inject drugs (PWID) and prisoners: A narrative review of the extant literature 1 Apr 2019 *Heroin Addiction and Related Clinical Problems*21(2):5-19
166. Schilling S, Maltezou HC, Fusco FM, De Iaco G, Brodt HR, Bannister B, Brouqui P, Carson G, Puro V, Gottschalk R, Ippolito G, Vetter N, Kojouharova M, Parmakova K, Skinhoej P, Siikamaki H, Perronne C, Adrami O, **Lambert J**, Lanini S, Hemmer R, Borg M, Fjellet AL, Brantsæter AB, Horban A, Strle F, Trilla Transportation capacity for patients with highly infectious diseases in Europe: a survey in 16 nations 1 Apr 2019 *Clinical Microbiology and Infection*21:e1-e5
167. Crowley D, **Lambert JS**, Betts-Symonds G, Cullen W, Kevans M, Kelly E, Laird E, McHugh T, McKiernan S, Miggin SJ, Murphy C, Murtagh R, O'Reilly D, Tobin C, Van Hout MC. The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017. *Euro Surveill.* 2019 Apr;24(14). doi: 10.2807/1560-7917.ES.2019.24.14.1800369.
168. Lee SH, Healy JE, **Lambert JS**. Single Core Genome Sequencing for Detection of both *Borrelia burgdorferi* Sensu Lato and Relapsing Fever Borrelia Species. *nt J Environ Res Public Health.* 2019 May 20;16(10). pii: E1779. doi: 10.3390/ijerph16101779.
169. Crowley D, Van Hout MC, Murphy C, Kelly E, **Lambert JS**, Cullen W. BMC Nurs. Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration. 2019 Jun 13;18:23. doi: 10.1186/s12912-019-0347-x. eCollection2019.
170. Crowley D, Murtagh R, Cullen W, Kevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, O'Connor E, O'Reilly D, Betts-Symonds G, Tobin C, Van Hout MC, **Lambert JS**. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. *Harm Reduct J.* 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
171. Adeniyi Oladele V, Chikwelu L Obi; Daniel T Goon; Benson C Iweriebor; Anthony I Ajayi; **John S Lambert** HIV-1 Drug Resistance Surveillance among Parturient Women on Anti-retroviral Therapy in the Eastern Cape, South Africa: Implications for Elimination of Mother-To-Child Transmission *Journal of Clinical Virology* J Clin Virol. 2019 Aug;117:89-95. doi: 10.1016/j.jcv.2019.06.003.
172. Crowley D, Murtagh R, Cullen W, **Lambert JS**, McHugh T, Van Hout MC. Hepatitis C virus infection in Irish drug users and prisoners - a scoping review. *BMC Infect Dis.* 2019 Aug 8;19(1):702. doi: 10.1186/s12879-019-4218-6.
173. Adeniyi OV, Obi CL, Goon DT, Iweriebor B, Ajayi AI, **Lambert J**, Okoh A. HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission. *J Clin Virol.* 2019 Aug;117:89-95. doi: 10.1016/j.jcv.2019.06.003. Epub 2019 Jun 14.
174. **Lambert JS**, HEP C: HEP CARE EUROPE - A service innovation project. HEP CHECK: Enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening - A prospective multi-site feasibility study. Author(s): Lambert, John *Journal of Antimicrobial Chemotherapy* Manuscript ID: JAC-2019-1289 Accepted 06-Sep-2019
175. Desmond Crowley , Walter Cullen ,**John S. Lambert** ,Marie Claire Van Hout. Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care. Published: September11019<https://doi.org/10.1371/journal.pone.0222186>
176. Morley D, **Lambert JS**, Hogan L, De Gascun C, Redmond N, Rutishauser R, Thanh C, Gibson E, Hobbs K, Bakkour S, Busch M, Farrell J, McGetrick P, Henrich TJ, *Rapid development of HIV elite control in a patient with acute infection* *BMC Infectious Diseases* (2019) 19:815 <https://doi.org/10.1186/s12879-019-4374-8>
177. Adeniyi OV, Selanto-Chairman N, Owolabi EO, Ajayi AI, Kayembe DK, Ter Goon D, Gordana A, **Lambert J**. Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant

- women with HIV in the Eastern Cape, South Africa. *BMC Public Health*. 2019 Oct 29;19(1):1407. doi: 10.1186/s12889-019-7769-y. PMID: 31664978
178. Barror S, Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Crowley D, Horan A, Naughton AM, Iglesias M, Ianache I, Lazar S, Popa I, McHugh T, Menezes D, Tinago W, **Lambert JS**. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. *J Antimicrob Chemother*. 2019 Nov 1;74(Supplement\_5):v39-v46. doi: 10.1093/jac/dkz455. PMID:31782499
  179. Moysa C, Murtagh R, **Lambert JS**. Potential Persistent *Borrelia* Infection and Response to Antibiotic Therapy; a Clinical Case Study and Review of Recent Literature. *Antibiotics (Basel)*. 2019 Nov 14;8(4). pii: E223. doi: 10.3390/antibiotics8040223. PMID: 31739409
  180. McCombe G, Almaazmi B, Cullen W, **Lambert JS**, Avramovic G, Murphy C, O'Connor M, Perry N, Ianache I, Lazar S, McHugh T, Surey J, Macías J, Vickerman P, Oprea C. Integrating primary and secondary care to optimize hepatitis C treatment: development and evaluation of a multidisciplinary educational Masterclass series. *J Antimicrob Chemother*. 2019 Nov 1;74(Supplement\_5):v24-v30. doi: 10.1093/jac/dkz453. PMID:31782501
  181. Nic An Riogh E, Swan D, McCombe G, O'Connor E, Avramovic G, Macías J, Oprea C, Story A, Surey J, Vickerman P, Ward Z, **Lambert JS**, Tinago W, Ianache I, Iglesias M, Cullen W. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. *J Antimicrob Chemother*. 2019 Nov 1;74(Supplement\_5):v31-v38. doi: 10.1093/jac/dkz454. PMID:31782502
  182. Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Iglesias M, Ianache I, Lazar S, Popa I, Menezes D, **Lambert JS**. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA. *Int J Infect Dis*. 2019 Nov 27. pii: S1201-9712(19)30467-9. doi: 10.1016/j.ijid.2019.11.027. [Epub ahead of print] PMID:31785401
  183. **Lambert JS**. An Overview of Tickborne Infections in Pregnancy and Outcomes in the Newborn: The Need for Prospective Studies. *Front Med (Lausanne)*. 2020 Mar 6;7:72. doi: 10.3389/fmed.2020.00072. eCollection 2020. Review.
  184. Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, **Lambert JS**, Muldoon E, Feeney E, Mallon PW, Tinago W; UCD ID Cohort Study. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort. *AIDS*. 2020 Apr 16. doi:10.1097/QAD.0000000000002541. [Epub ahead of print] PMID: 32310899
  185. Freitas IT, Tinago W, Sawa H, McAndrews J, Doak B, Prior-Fuller C, Sheehan G, **Lambert JS**, Muldoon E, Cotter AG, Hall WW, Mallon PWG, Carr MJ. Interferon lambda rs368234815  $\Delta G/\Delta G$  is associated with higher  $D4^{CD8}$  T-cell ratio in treated HIV-1 infection. *AIDS Res Ther*. 2020 Apr 15;17(1):13. doi: 10.1186/s12981-020-00269-0.
  186. O'Kelly B, Murtagh R, **Lambert JS**. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review. *Ther Drug Monit*. 2020 Apr;42(2):229-244. doi: 10.1097/FTD.0000000000000735. PMID: 32004247
  187. Bukkems V, Necsoi C, Tenorio CH, Garcia C, Rockstroh J, Schwarze-Zander C, **Lambert JS**, Burger D, Konopnicki D, Colbers A; PANNA network. Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study. *Clin Infect Dis*. 2020 Apr 24;ciaa488. doi: 10.1093/cid/ciaa488. Epub ahead of print. PMID: 32330231.
  188. Michaelis IA, Nielsen M, Carty C, Wolff M, Sabin CA, **Lambert JS**. Late diagnosis of human immunodeficiency virus infection is linked to higher rates of epilepsy in children in the Eastern Cape of South Africa. *South Afr J HIV Med*. 2020 Jun 30;21(1):1047. doi: 10.4102/sajhivmed.v21i1.1047. PMID: 32670626; PMCID: PMC7343945.
  189. O'Kelly Brendan, McGettrick Padraig, Angelov Daniel, Fay Michael, McGinty Tara, Aoife G. Cotter, Sheehan Gerard, **Lambert John S**. Outcome of a patient with refractory Hodgkin

- lymphoma on pembrolizumab, infected with SARS-CoV-2. First published: 07 May 2020  
<https://doi.org/10.1111/bjh.16798> BJH British Journal of Haematology Volume 190, Issue 1, July 2020
190. Raben D ,Hoekstra M, Combs L, Sullivan AK, Lazarus JV, **Lambert JS**, Simões D, Streinu-Cercel A, Rockstroh JK A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB on behalf of the HepHIV Conference Organizing Committee, the EuroTEST Steering Committee, INTEGRATE Steering Committee First published: 24 April 2020  
<https://doi.org/10.1111/hiv.12844> HIV Medicine Volume 21, Issue 6 July 2020.
  191. Connolly SP, Avramovic G, Cullen W, McHugh T, O'Connor E, Mc Combe G, Crowley D, Naughton AM, Horan A, **Lambert JS**. HepCare Ireland-a service innovation project. *Ir J Med Sci.* 2020 Aug 6. doi: 10.1007/s11845-020-02324-1. Epub ahead of print. PMID: 32761548.
  192. O'Kelly B, **Lambert JS**. Vector-borne diseases in pregnancy. *Ther Adv Infect Dis.* 2020 Sep 1;7:2049936120941725. doi: 10.1177/2049936120941725. PMID: 32944240; PMCID: PMC7469740.
  193. Cullen W, Avramovic G, Broughan J *et al*. Study Protocol: Prospective, observational, cohort study of COVID-19 in General Practice (North Dublin COVID-19 Cohort ['ANTICIPATE'] Study) [version 1; peer review: awaiting peer review]. *HRB Open Res* 2020, **3**:67 (<https://doi.org/10.12688/hrbopenres.13135.1>)
  194. Avramovic G, Reilly M, Cullen W, Macías J, McCombe G, McHugh T, Oprea C, Story A, Surey J, Sabin C, Bivegete S, Vickerman P, Walker J, Ward Z, **Lambert JS**. HEPCARE EUROPE- A Case study of a Service Innovation Project Aiming at Improving the Elimination of HCV in Vulnerable Populations in Four European Cities. *Int J Infect Dis.* 2020 Sep 26:S1201-9712(20)32161-5. doi: 10.1016/j.ijid.2020.09.1445. Epub ahead of print. PMID: 32992012.

#### Non-Refereed Publications

##### Articles

1. **Lambert JS**. Maternal and perinatal issues of HIV. *Peds Annals*, 1990; 19(8)468-472.
155. Brandriss MW, **Lambert JS**. Cardiac infections. In: *Practical Approach to Infectious Diseases, 3rd Edition*, Reese RE, Betts RF (eds.), Little, Brown and Company, Boston, 1991; pp. 278-304.
156. **Lambert JS**. Clinical simulations in the management of HIV disease. Medical Age Publishing, Norwalk, CT, June 1992.
157. **Lambert JS**. Maternal-fetal transmission of HIV-1 infection. *Pediatr Ann*,1993;22;413-16.
158. **Lambert JS**. HIV prevention and treatment through immune modulation--Where are we going? *AIDS Reader*, Jan-Feb 1995.
159. **Lambert JS**. Passive immunotherapy for prevention and treatment of HIV infection. *AIDS Reader*, Mar-Apr 1995, pp. 59-63.
160. Anderson J; **Lambert JS** & Nogueira SA : Manual para o acompanhamento clínico dagestante infectada pelo HIV. primeira edição, 71 p., UFRJ/Fogarty Foundation, 1996.
161. **Lambert JS**; Nogueira SA e Abreu TF: Manual para o acompanhamento da criança infectada pelo HIV. Primeira edição, 92 p., UFRJ/Fogarty Foundation, 1996.

162. **Lambert JS** & Nogueira AS: Manual para o tratamento ambulatorial da mulher infectada pelo HIV, primeira edição, 124 p., UFRJ/Fogarty Foundation, 1997.
163. **Lambert JS** & Nogueira S A : Manual para o acompanhamento clínico da gestante infectada pelo HIV, terceira edição, 84 p., UFRJ/Fogarty/ JFAP, 1998.
164. **Lambert JS**; Nogueira SA e Abreu TF: Manual para o acompanhamento da criança infectada pelo HIV, segunda edição, 116 p., UFRJ/WAF, 1999.
165. **Lambert JS**, Nogueira SA, Anderson E : Manual for the follow up of pregnant women infected by HIV, 1st edition, 1999
166. **Lambert JS**, Nogueira SA, Dover A: El manual para el cuidado médico integrado de la mujer embarazada e infectada pelo VIH, primera edition en espanol, 1999
167. Contoreggi C, Rexroad V, **Lambert JS**. Infectious complications in the Injection Drug User. Book chapter in *Current Therapy of Infectious Diseases*, 2<sup>nd</sup> edn, Ed David Schossberg, 2000.
168. **Lambert JS** & Nogueira S A :Manual para o acompanhamento clínico da gestante infectada pelo HIV, quarta edição, 101 p., UFRJ/WAF, 2000.
169. Nogueira SA, Reis M & **Lambert JS**: Manual para o diagnóstico e tratamento de infecções na gravidez. 1<sup>a</sup> edição, 2000, p.131
170. **Lambert JS**, Book Chapter on Therapeutic HIV Vaccines, in *Antiretroviral Therapy*, ed Erik DA De Clercq, ASM Press, 2001.
171. **Lambert JS**, Nogueira S A & Abreu T: Manual para el manejo clinico del nino infectado pelo HIV, 1<sup>a</sup> edição, 2001, p.121
172. **Lambert JS**, Nogueira S A & Abreu T: Manual para o acompanhamento da criança infectada pelo HIV- 3<sup>a</sup>edição, 2001.
173. **Lambert JS**, Nogueira SA, Abreu TF. Manual para a acompanhamento da crianca infectada pelo HIV, Rio de Janeiro, Brazil 2004
174. **Lambert JS**, Nogueira SA, Saraogi RM. Manual for the clinical care of HIV infected pregnant women. Bombay, India 2004.
175. **Lambert JS**, Nogueira SA, Joshi Shubhada Y. Manual for the care of HIV infected children. Bombay, India 2004
176. **Lambert JS**, Clapson M. In search of a paediatric HIV vaccine: scientific and ethical issues. *HIV Nursing*, Volume 5, Number 4, Winter 2005.
177. Eramova I, Matic S, Munz M (eds). *HIV/AIDS treatment and care: Clinical protocols for the WHO European Region*. Copenhagen WHO Regional Office for Europe, 2007.(**JS Lambert**: appendix author).
178. Mc Ginty T, **Lambert,JS**. Rabies- An Irish View, *Modern Medicine*, The Irish Journal of Clinical

Medicine, Volume 39 Number 4, 2009.

179. **Lambert JS**, HPV Infection- A Vaccine Preventable Disease, Medical Independent, Issue 24 Volume 1, 23 December 2010.
180. **Lambert JS**, Management of hepatitis B and C, Medical Independent, Issue 6 Volume 3, 22 March 2012.

## 16- ABSTRACTS

1. Keefer MC, **Lambert JS**, Mayer CM, Chin NP, Long M, Cummings T, Menegus MA. Evaluation of a rapid enzyme-linked immunoassay for the diagnosis of Herpes simplex virus (HSV)-Kodak Surecell™ Herpes (HSV) test. Program and Abstracts, 89th Annual Meeting, American Society for Microbiology, New Orleans, LA, Abstract C-13, p. 395, May 14-18, 1989.
2. **Lambert JS**, Long M, Mayer C, Signs D, Keefer MC, Bixler D, Reichman R. Prevalence of *Trichomonas vaginalis* relative to other sexually transmitted diseases in unselected males seen at a public health department STD clinic. Program & Abstracts, 89th Annual Meeting of the American Society for Microbiology, New Orleans, LA, Abstract C-360, p453, May 14-18, 1989.
3. **Lambert JS**, Dolin R, Seidlin M, Knupp C, Morse G, McLaren C, Plank C, Reichman RC. '2'3' Dideoxyinosine (ddI) administered twice daily to patients with AIDS ARC: 29th Interscience Conference on Antimicrobiology Agents & Chemotherapy. Houston, TX, September 17-20, 1989.
4. Keefer MC, **Lambert JS**, Coury-Doniger P, Fein D, Mattison HR, Menegus MA. Genital ulcer disease (GUD) in a sexually transmitted diseases (STD) clinic. 29th Interscience Conference on Antimicrobial Agents & Chemotherapy, Houston, TX, September 17-20, 1989.
5. **Lambert JS**, Insel R, Weissbach N, Keefer MC, Reid J, Anderson P. The immunogenicity of *Streptococcus pneumoniae* (Pn) conjugate vaccines in patients with human immunodeficiency virus (HIV) infections. 6th International Conference on AIDS, San Francisco, CA, June 20-24, 1990.
6. Keefer MC, Roberts NJ Jr, Bonnez W, **Lambert JS**, Dolin R, Reichman R. HIV-1 rgp160-specific cellular immune responses by recipients of a live vaccinia-rgp160 vaccine. 3rd Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Clearwater, FL, October 1-5, 1990.
7. Reichman R, **Lambert JS**, Strussenberg J, Dolin R. Decreased dideoxyinosine (ddi) sensitivity of HIV isolates obtained from long term recipients of ddi. 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991.
8. Allain J-P, Matthews T, Coombs R, **Lambert JS**, Wara D, Devash Y, Bryson Y. Antibody to V3 loop peptide does not predict vertical transmission of HIV. 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991.
9. **Lambert JS**, Stiehm ER. Passive immunity in the prevention of maternal-fetal transmission. The New York Academy of Sciences Conference, Pediatric AIDS, Washington, DC, November 18-21, 1992.

10. Frenkel LM, Demeter LM, Wagner L, Tejani NA, **Lambert JS**, Blumberg BM, Epstein LG, Strussenberg JG, Reichman R. Perinatal transmission of an AZT resistance mutation (AZT-R) from a mother to her infant. *Keystone Symposia on Molecular & Cellular Biology*. Albuquerque, NM. March 29-April 25, 1993.
11. **Lambert JS**, Metlay L. Perinatal HIV infection masquerading as SIDS. *Keystone Symposia on Molecular and Cellular Biology*. Albuquerque, NM. March 29 - April 25, 1993. *Keystone Symposia on Molecular & Cellular Biology*. Albuquerque, NM. March 29-April 25, 1993.
12. Reichman RC<sup>1</sup>, Tejani N, **Lambert JS**, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. *Antiviral Res.* 1993 Apr;20(4):267-77.
13. **Lambert JS**, McNamara J, Katz S, Fenton T, Nichols J, Roberts NJ Jr. Safety and immunogenicity of recombinant envelope HIV vaccines in asymptomatic HIV-infected children. 1st National Conference on Human Retroviruses and Related Infections, Washington, DC, Dec 12-16, 1993.
14. **Lambert JS**, Wright P, Fast P, Walker MC, Stablein D, Gorse G, Anderson E, McElrath J, Watts H, Wara D, Landers D, Abramowicz J, Keefer M, Anderson J, Francis D. A phase I, placebo-controlled, safety and immunogenicity trial of Genentech MN rgp120 HIV-1 vaccine in HIV-infected pregnant women with CD4  $\geq$  400. Conference on AIDS Vaccine Development (Seventh NCVDG Meeting), Reston, VA, Nov. 6-10, 1994.
15. **Lambert JS**, Clements ML, Viscidi R, Schwartz DH, Clayman B, the AIDS Vaccine Evaluation Group, Johns Hopkins University, Baltimore, MD; NIH, Bethesda, MD. Measurement of antibody to HIV-1 gp160 in mucosal specimens of asymptomatic seropositive volunteers immunized with parenterally administered ImmunoAG rgp 160 IIIB. Conference on AIDS Vaccine Development (Seventh NCVDG Meeting), Reston, VA, Nov. 6-10, 1994.
16. Schwartz DH, Sridharan G, Clements ML, **Lambert JS**, Arango-Jaramillo S. PBMC resistance to in vitro challenge with HIV-1<sub>MN</sub> after ALVAC-MN gp160 priming and SF2 gp120 boosting (AVEG trial 012A): A potential system for vaccine evaluation. Conference on AIDS Vaccine Development (Seventh NCVDG Meeting), Reston, VA, Nov. 6-10, 1994.
17. **Lambert JS**, Fletcher C, Mofenson L, Stiehler ER, Moye J, Meyer W, Nemo G, Mathieson B, Hirsch G. Pharmacokinetics (PK) of hyperimmune HIV immunoglobulin (HIVIG) in HIV<sup>-</sup> pregnant women & newborns. Second National Conference on Human Retroviruses and Related Infections, Washington, DC, Jan. 1995.
18. **Lambert JS**, McNamara J, Katz S, Fenton T, Nichols J, Roberts NJ Jr. Safety and immunogenicity of recombinant envelope HIV vaccines in asymptomatic HIV-infected children. Second National Conference on Human Retroviruses and Related Infections, Washington, DC, Jan. 1995.
19. Mofensen I, **Lambert JS**, Fletcher C, Stiehler ER, Moye J, Meyer W, Nemo G, Mathieson B, Hirsch G. Pharmacokinetics of p24 antibody (Ab) in HIV<sup>-</sup> pregnant & newborns receiving hyperimmune HIV immunoglobulin (HIVIG) in ACTG protocol 185. Keystone Conference, March 1995.
20. **Lambert JS**. Passive immunotherapy for prevention and treatment of HIV-1 infection. AmFAR



Seminar, The AIDS Reader Mar/Apr 1995.

21. **Lambert JS**, Vaccines for children with HIV. Child Health 2000, 2nd World Congress & Exposition, Vancouver, Canada, May 30-June 3, 1995.
22. Fletcher CV, **Lambert JS**, Mofenson L, Stiehm ER, Meyer W, Moye J, Page Lm, Nemo G, Mathieson B, Hirsch G. Transplacental passage, safety and pharmacokinetics (PK) of hyperimmune HIV immunoglobulin (HIVIG) in newborns of HIV+ women. 35th ICAAC, San Francisco, CA, Sept. 1995.
23. **Lambert JS**, Mofenson L, Fletcher C, Stiehm ER, Meyer W, Moye J, Nemo G, Mathieson B, Hirsch G. Pharmacokinetics (PK) & safety of hyperimmune HIV immunoglobulin (HIVIG) in pregnant HIV + women. 35th ICAAC, San Francisco, CA, Sept. 1995.
24. **Lambert, JS**, Mofenson L, Nelson K, Chuachoowong R, Farzadegan H. Safety of HIVIG in maternal fetal transmission of HIV: Implications for Thailand. Third International Conference, AIDS in Asia and Pacific, Sept. 1995.
25. Keefer MC, **Lambert JS**, Koff W, Weinhold K, Wolff M, Clements ML, Hosein B, Demeter L, Boyle RW, Dolin R, NIAID AIDS Vaccine Clinical Trials Network. A Phase I Study of a Multivalent HIV-1 Peptide Vaccine in HIV-1 Uninfected Subjects. Infections Diseases Society of America, 1995.
26. Farzadegan H, Vlahov D, Chaplinskiene K, Nelson K, **Lambert JS**, Halsey N, Bollinger R, Jackson B, Saah A. Cross-neutralization of Domestic and International HIV-1 Isolates by Autologous Sera and HIVIG. Third Conference on Retroviruses and Opportunistic Infections, Infections Diseases Society of America, Jan 1996.
27. **Lambert JS**, Wright P, Gorse G, Anderson E, McElrath J, Abramowicz J, Keefer M, Anderson J, Fast P, Walker MC, McNamara J, Hsiu R, Francis D. Representing the NIH NIAID Sponsored, AIDS vaccine Evaluation Group, Genentech, S. San Francisco CA. A Phase I Placebo-Controlled, Safety & Immunogenicity Trial of Genentech MN rgp120 HIV-1 Vaccine in HIV-Infected Pregnant Women with CD4  $\geq$ 400. Third Conference on Retroviruses and Opportunistic Infections, Infectious Diseases Society of America, Jan 1996.
28. **Lambert JS**, Wright P, McElrath J, Wara D, Keefer M, Anderson J, Fast P, Walker MC, McNamara J, Hsiu R, Francis D. Representing the NIH/NIAID Sponsored, AIDS Vaccine Evaluation Group, Genentech, S. San Francisco CA. A Phase I Placebo-Controlled, Safety & Immunogenicity Trial of Genentech MN rgp120 HIV-1 Vaccine in HIV-Infected Pregnant Women with CD4  $\geq$ 400. Eighth NCVDG Meeting, Feb 1996.
29. Nogueira SA, Zornitta M, Rosa S, Filho EJ, Rodrigues K, Candido A, Simões I, Imeko F & **Lambert JS**: Avaliação dos conhecimentos em relação à AIDS de um grupo de gestantes de 2 Serviços Públicos de Pré-Natal no Rio de Janeiro. IX Congresso Brasileiro de Infectologia - Recife, 1996.
30. **Lambert JS**, McNamara J, Katz S, Livingston R, Moye J. Safety and Immunogenicity of HIV Recombinant Envelope Vaccines in HIV-Infected Infants and Children. The American Pediatric Society 1996.

31. Nogueira S, Zormitta M, Rosa S, Filho Esau J, Perisse AR, Rodriguez K, Candido A, Simoes I, Imeko F, **Lambert JS**. Avaliacao dos conhecimentos em relacao a AIDS de um grupo de gestante de 2 servicos publicos de pre-natal no Rio de Janeiro. Servico de DIP - HUCFF - UFRJ, HSE e Fogarty Foundation.
32. Mascola JR, Louder MK, Vancott TC, Sapan CV, **Lambert JS**, Muenz LR, Birx DL, Robb ML, Potent and synergistic neutralization of primary HIV-1 isolates by hyperimmune anti-HIV immunoglobulin (HIV-IG<sup>TM</sup>) combined with monoclonal antibodies 2F5 and 2G12. 4<sup>th</sup> Conference on Retroviruses and Opportunistic Infections January, 1997.
33. Mascola JR, Louder MK, Vancotti TC, Sapan CV, **Lambert JS**, Muenz LR, Birx DL, Robb ML. Potent and Synergistic Neutralization of Primary HIV-1 Isolates by Hyperimmune anti-HIV Immunoglobulin (HIV-IG<sup>TM</sup>) combined with Monoclonal Antibodies 2F5 and 2G12. 4<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January, 1997
34. B, de Oliveira RH, Pilotto JH, Zomila M, **Lambert JS**. A educacao de profissionais de saude envolvidos nos cuidados de pre-natal como parte da estrategia para prevencao da transmissao vertical do HIV. Programa de Assistencia Integral a Gestante HIV Positiva (HU-CFF/IPPMG, HSE, HEC, HGNI, Fogarty Foundation)
35. Nogueira SA, Filho EJ, Costa TP, D'Ipollito M, Pilotto JH, Garcia MI, Veloso, VG, Grinsztejn B, **Lambert, JS**. Prevalencia de infeccoes associadas, no primeiro atendimento do pre natal, em gestantes infectadas pelo HIV no Rio de Janeiro. Programa de Assistencial Integral a Gestante HIV Positiva (HU-CFF/IPPMG, HSE, HGNI, HEC, Fogarty Foundation).
36. Nogueira SA, Filho EJ, Costa TP, D'Ipollito M, Pilotto JH, Garcia MI, Veloso VG, Grinsztejn B, **Lambert JS**. Prevalência de infecções associadas, no primeiro atendimento de pré natal, em gestantes infectadas pelo HIV no Rio de Janeiro. The Brazilian Journal of Infectious Diseases, Volume 1, Supp 1, May 1997.
37. Nogueira SA, Filho EJ, Costa TP, D Ipólito M, **Lambert JS** et al.: Prevalência de infecções associadas, ao primeiro atendimento do pré-natal, em gestantes infectadas pelo HIV no Rio de Janeiro 8th Pan American e 10th Congresso Brasileiro de Infectologia - Salvador, maio de 1997.
38. Nogueira SA; Filho EJ, Abreu T.F, **Lambert JS** et al.: A educação de profissionais de saúde envolvidos nos cuidados de pré-natal como parte da estratégia para prevenção da transmissão vertical do HIV. 8th Pan American e 10th Congresso Brasileiro de Infectologia Salvador, maio de 1997.
39. Nogueira SA, Pilotto JH, Navarini A, **Lambert JS** et al.: Compliance pattern of 076 regimen in a developing country: Rio de Janeiro, Brazil. Conference on Global Strategies for the Prevention of HIV Transmission from mothers to infants - Washington, Sept.3-6. 1997.
40. Teles J, Oliveira R, Nogueira SA, **Lambert JS**, Mitchell, Tanuri A: Vertical transmission of HIV - 1 subtypes in Rio de Janeiro, Brazil Conference on Global Strategies for the Prevention of HIV Transmission from mothers to infants - Washington, Sept.3-6. 1997.
41. Nogueira SA, **Lambert JS**, et al. Avoidance of Breast feeding by HIV Infected Women: Strategy of a multiprofessional team in the developing world. 12<sup>th</sup> World AIDS Conference, Geneva, Switzerland, June-July 1998.

42. **Lambert JS**, Abreu T, Plaisance K, Nogueira S, Evangelista L, Oliveira R, Rangel R, Knupp C. Comparative bioavailability of once and twice daily regimens of didanosine in pediatric patients with AIDS. 12<sup>th</sup> World AIDS Conference, Geneva, Switzerland, June-July 1998.
43. **Lambert JS**, et al. Risk factors for perinatal HIV transmission in women/infants receiving standard zidovudine (ZDV) prophylaxis. 12<sup>th</sup> World AIDS Conference, Geneva, Switzerland, June-July 1998.
44. **Lambert JS**, Abreu T, Nogueira SA et al.: Comparative bioavailability of once and twice daily regimens of didanosine in pediatric patients with AIDS. XII International Conference on AIDS, Geneva, 1998.
45. Nogueira SA, Garcia MI, Mercadante R, **Lambert JS** et al.: Avoidance of breastfeeding by HIV infected woman: strategy of a multi-professional team in a developing world. XII International Conference on AIDS, Geneva, 1998.
46. Serra MC, Nogueira SA, **Lambert JS** et al.: Prevalence of HIV among women and children evaluated in an emergency room of an inner city hospital in Rio de Janeiro. XII International Conference on AIDS, Geneva, 1998.
47. Mofenson L, **Lambert JS**, Stiehm ER, et al. Risk factors for adverse pregnancy outcomes (APO) in HIV-infected pregnant women in PACTG 185. 6<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January 1999.
48. Watts H, Mofenson L, Whitehouse J, Read J, Stiehm R, **Lambert JS**, Fowler M, Nemo G. Complications according to mode of delivery among HIV-positive women with CD4 counts <500. 6<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January 1999.
49. K. Ganesh, Suniti Solomon, N Kuramasami, Purnima Madhivanan, SN Mothi, **Lambert JS**. Antenatal Screen in India: Economic Challenges. 2<sup>nd</sup> Conference on Global Strategies for the prevention of HIV Transmission from Mothers to Infants. September 1-6 1999, Montreal, Canada. Abstract No: 489.
50. **Lambert JS**, Johnson D, McFarland E, Fenton T, McNamara J, Puresan P, Hawkins E, Bouquin P, El Habib R, Excler J-L. A phase I study of the safety and immunogenicity of an HIV-1 alvac vaccine in children born to HIV infected mothers: preliminary results. 2<sup>nd</sup> Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Can, Sept.1-6. 1999
51. Nogueira SA, Abreu T, Oliveira R, **Lambert JS** et al: Implementation of 076 in a developing country using a multidisciplinary team approach. II Conference on Global Strategies for the Prevention of HIV Transmission from mothers to infants - Montreal, Can, Sept.1-6. 1999.
52. Nogueira S, Abreu T, Oliveira R, Costa T, Peres M, Halpern M, Barbosa R, Sztajn bok D, Gomes V, Bonfim D, Chermont MC & **Lambert JS**. Implementation of 076 in a developing country using a multidisciplinary team approach. 2<sup>nd</sup> Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Can, Sept.1-6. 1999
53. Souza E, **Lambert JS**, Constantine N, Saville R, Alquichire Bueno C, Ketema F, Edelman D, Farley J, University of Maryland Medicine & the Institute of Human Virology, Baltimore MD,

- USA. Seroprevalence of viral sexually transmitted diseases in pregnant women at Recife, Brazil. 2<sup>nd</sup> Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Can, Sept.1-6. 1999
54. Sztajnbock D, Rodrigues R, Santos AL, Abreu T, **Lambert JS**, Farley J, Nogueira S. Prevalence of HIV, Syphilis and Hepatitis B infection in 1000 pregnant women from an inner city hospital of Rio de Janeiro. 2<sup>nd</sup> Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Can, Sept.1-6. 1999.
  55. Sztajnbock Denise; Rodrigues R; Santos AL; Abreu T; **Lambert JS**; Farley J, Nogueira SA: Prevalence of HIV, Syphilis and Hepatitis B infection in 1000 pregnant women from an inner city hospital of Rio de Janeiro. II Conference on Global Strategies for the Prevention of HIV Transmission from mothers to infants - Montréal, Can, Sept.1-6. 1999.
  56. Mofenson L, **Lambert JS** et al. Performance Characteristics of HIV-1 Culture, DNA PCR or Quantitative RNA for Early Diagnosis of Perinatal HIV-1 Infection. 7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January 2000.
  57. L. Mofenson, R. Harris, E.R. Stiehm, **Lambert JS**, Moye, W. Meyer. Performance Characteristics of HIV-1 Culture, DNA PCR or Quantitative RNA for Early Diagnosis of Perinatal HIV-1 Infection. 7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, January 2000.
  58. Nogueira SA, **Lambert JS** et al. Avaliação Da Tolerância E Eficácia Da Combinação Em Dose Fixa de AZT/3TC Para Gestantes Infectadas Pelo HIV E Seus Recém-nascidos., Rio de Janeiro Pediatric ID conference, 2000.
  59. Nogueira AS, Abreu T, Oliveira RH, Sábia MC, Costa TP, **Lambert JS**: Prevenção da transmissão vertical do HIV: resultados de um programa de assistência multidisciplinar XII Congresso Brasileiro de Infectologia Pediátrica Rio de Janeiro, 27 a 30 de junho de 2000
  60. Abreu T, Nogueira TA, Evangelista L, Oliveira R, Plaisance K, **Lambert JS**; Comparação de dose única de didanosina (DDI) versus dose dupla diária para tratamento de infecção sintomática pelo HIV em crianças – um estudo de tolerância e farmacocinética. XII Congresso Brasileiro de Infectologia Pediátrica Rio de Janeiro, 27 a 30 de junho de 2000
  61. Sztajnbock D, Nogueira SA, Raimunda MR, **Lambert JS** : Prevalência da infecção pelo HIV, vírus da hepatite B e *Treponema pallidum* em gestantes atendidas em maternidade pública do Rio de Janeiro. . XII Congresso Brasileiro de Infectologia Pediátrica Rio de Janeiro, 27 a 30 de junho de 2000.
  62. Mofenson L, **Lambert JS** et al. Association of Zidovudine (ZDV) Genotypic Resistance with Perinatal HIV Transmission in Women Receiving ZDV in Pediatric AIDS Clinical Trials Group (PACTG) Protocol 185. 8<sup>th</sup> International AIDS Conference, July 2000.
  63. Kieran J, Cotter A, O'Connor EI, Khoo S, Gibbons S, Brennan M, **Lambert JS**. Adequate trough levels of lopinavir/ritonavir achieved in pregnancy using standard dosing of new formulation twice daily. Late Breaker poster presentation, 2000.
  64. Nogueira SA, **Lambert JS**, Albuquerque AL, Rodrigues R, Reis S, Bornia R, Dias M, Stanjbock D, Constantine N. Teste rápido anti HIV: sua utilização no parto para prevenção da transmissão

vertical. Congress of Tropical Medicine Salvador, Brazil 2000.

65. Sarvade M, Madhivanan P, Kumarasmi N, Yephthomi T, Chakrapani V, Begum R, **Lambert JS**, Solomon S, Clinical profile of HIV infected children attending a HIV care center in South India. ICAAP, 2000.
66. Nogueira S A, **Lambert JS**, Albuquerque AL, Bórnia R, Sztanbok D, Dias M, Constantine N: Assessing Rapid HIV Testing in Labor and Delivery: a pilot study from Rio de Janeiro, p.254. 8th Conference on Retrovirus and Opportunistic Infections, February 4-8, 2001, Chicago, US.
67. **Lambert JS**, Nogueira S A, Abreu T, Costa T, Andrade M, Bondarowski M, Halpern M, Barbosa R: Pilot study to evaluate the safety and feasibility of the administration of AZT/3TC to HIV pregnant women and their infants in Rio de Janeiro, Brazil .poster n.203 The 3rd conference on Global Strategies for the prevention of HIV transmission from mothers to Infants, September 9-13, 2001, Kampala, Uganda.
68. Nogueira S A, **Lambert JS**, Albuquerque AL, Raimunda R, Reis S, Bórnia R, Dias M, Barbosa R : Two rapid tests at labor to identify HIV infection among pregnant women: evaluation of presentation and performance in Rio de Janeiro, Brazil. Poster 216. The 3rd conference on Global Strategies for the prevention of HIV transmission from mothers to Infants, September 9-13, 2001, Kampala, Uganda.
69. Nogueira S A, Abreu T, Costa T, Oliveira R, Machado ES, Miriam M, Abreu I, Bondarowski M, Mercadante R, Garcia MFL, Raimunda R, **Lambert JS**: Five years experience of a program to prevent HIV vertical transmission in a public university of a transitional country. Poster n.311. . The 3rd conference on Global Strategies for the prevention of HIV transmission from mothers to Infants, September 9-13, 2001, Uganda.
70. Brundage RC, Fletcher CV, Stiehm ER, **Lambert JS**, Mofenson LM, Moye J, Ng J, Hering M, Harris R and the PACTG 185 Team. Population Pharmacokinetics of Zidovudine in HIV-Exposed Neonates. CROI, Chicago USA 2001.
71. **Lambert JS**, Nogueira S, Abreu T, Costa T, Andrade M, Bondarovsky M, Halpern M, Barbosa R. A pilot study to evaluate the safety and feasibility of the administration of AZT.3TC to HIV pregnant women and their infants in Rio de Janeiro, Brazil. Global Strategies Conference Uganda 2001.
72. Nogueira SA, Machado ES, Rodrigues MR, Reis SM, **Lambert JS**. A disponibilidade do resultado do teste anti HIV na gestacao: um problema a ser resolvido. Brazilian, Infectious Disease Conference, Recife, 2001
73. Nogueira S A, **Lambert JS**, Albuquerque AL, Rodrigues MR, Reis S, Bórnia R, Dias M, Sztanbok D, Constantine N: Teste rápido anti HIV: sua utilização no parto para prevenção da transmissão vertical. XXXVII Congresso da Sociedade Brasileira de Medicina Tropical Salvador, Ba., 11 a 14 de março de 2001 abstracts publicados no supl. da Revista da Sociedade Brasileira de Medicina Tropical, vol. 34, supl I, 2001.
74. Nogueira AS, Machado ES, Rodrigues MR, Reis S & **Lambert JS**: A disponibilidade do resultado do teste anti-HIV na gestação: um problema a ser resolvido . XXXVII Congresso da Sociedade Brasileira de Medicina Tropical Salvador, Ba., 11 a 14 de março de 2001 abstracts publicados no

supl. da Revista da Sociedade Brasileira de Medicina Tropical, vol. 34, supl I, 2001.

75. Machado E, **Lambert JS**, Afonso AO, Cunha SC, Caride E, Nogueira S, Oliveira RH, Watson DC, Sill AM, DeVico AI and Tanuri A. Distribuicao dos Subtipos de HIV-1 em Crianças Soropositivas Acompanhadas no Ippmg – Rio De Janeiro. . XXXVIII Congress de Soliedade Brasileira de Medicina Tropical, Feb 2002: 018, page 45.
76. Nogueira S, Correa R, Holanda M, Cruz M & **Lambert JS**. Prevalencia de Strongyloides Stercoralis em Pacientes Infectados Pelo HTLV-1 Provenientes de uma Casuistica Hospitalar. XXXVIII Congress de Soliedade Brasileira de Medicina Tropical, Feb 2002: 430, page 251.
77. JF Poulin, R Cheynier, M Sylestre, RP Sekaly, C Tsokas, PM Girard, J Modai, S Kinloch, B Gazzard, L Perrin, L Goh, S Pratt, **Lambert JS**. Thymic Reconstitution in Primary HIV Infection (PHI) following HAART is Polyclonal. Abstract.
78. Beatriz A Carvalho, **Lambert JS**, Barbosa M, Ney A Grillo. Funded by the Elizabeth GlaserPaediatric AIDS foundation. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças April 2002, T26, page 29-30.
79. Elizabeth S Machado, **Lambert JS**, Watson DC, et al. Analise genotipica em crianças HIV-1 + em uso de terapia antiretroviral dupla ou tripla: resistencia ou baixa adesao. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças April 2002, T33, page 35.
80. **Lambert JS**. Mitochondrial Toxicity and HIV Therapy .IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças. April 2002, Pg 12.
81. Nogueira S, Barretto J, da Costa, **Lambert JS**, Dias Marcos. Estrategias Educacionais pra a capacitacao de professionals de saude da transmissio vertical do HIV. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças, April 2002, T54, page 42.
82. Nogueira S, Machado ES, da Costa TP, Maan MA, Rodrigues R & **Lambert JS**. Prevalencia de Co-infeccoes numa coorte de gestantes infectadas pelo HIV no Rio de Janeiro. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças April 2002, T14, page 28 .
83. Nogueira S, Machado ES, da Costa TP, Abreu TF, Oliveira R, Bondarowski M, and **Lambert JS**. Evolucao do Uso de anti-retrovirais e Tipo de parto Num Programa de prevencao da transmissao vertical do HIV. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças April 2002, T15, page 28.
84. Nogueira S, Machado ES, da Costa TP, Abreu TF, and **Lambert JS**. Infeccao pelo HIV em Adolescentes Gestantes: Mais um Problema A ser Enfrentado. IV Conferencia sobre Infeccao pelo HIV Em Mulchers E Crianças April 2002, T16, page 28.
85. Mofenson LM, **Lambert JS**, Stiehm ER, Kagan R, Moye J, Harris DR, Bethel J, Meyer W, Fowler MG, Mathieson B, Nemo G. Case Control Study of Perinatal HIV-1 Transmission and Genotypic and Phenotypic Markers of Reduced Susceptibility to Zidovudine (ZDV) and other Antiretrovirals. *Potential Abstract Barcelona July 2002*.
86. Nogueira S A, **Lambert JS**. Co-infection with Toxoplasma gondii in a cohort of HIV infected pregnant women. Abstract submitted to XIV AIDS Conference, Barcelona 2002 (ref: 3694).

87. Nogeria S, Machado E, Costa T, Abreu T, Taveraes M, Oliveria RH & **Lambert JS**. Evolution of the use of antiretrovirals (ARV) to prevent HIV MTCT in Rio de Janeiro, Brazil. Abstract submitted to XIV AIDS Conference, Barcelona 2002.
88. Nogueira S A, **Lambert JS**. Changes over time in the use of antiretrovirals to prevent vertical transmission of HIV. Abstract submitted to XIV AIDS Conference, Barcelona 2002 (ref: 3751).
89. McFarland E, Johnson D, Fenton T, Muresan P, McNamara J, Hawkins E, Estep S, Read J, Gunurathan S, **Lambert JS**. A Phase I/II study of the Safety and Immunogenicity of an HIV-1 ALVAC Vaccine in Infants Born to HIV-Infected Mothers. Abstract 99, Oral Presentation 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Feb 10-14, 2003, Boston, Massachusetts, USA.
90. Johnson D, McFarland E, Muresan P, Fenton T, **Lambert JS**, McNamara J, Hawkins E, Boquin P, Estep S, Read J, Gunurathan S PACTG326: A Phase I/II study of the Safety and Immunogenicity of an HIV-1 ALVAC Vaccine in Infants Born to HIV-Infected Mothers. Abstract 404, 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Feb 10-14, 2003, Boston, Massachusetts, USA.
91. Watts DH, **Lambert JS**, Stiehm ER, Harris DR, Bethel J, Mofenson L, Mathieson B, Fowler MG, Nemo G. Clinical, Virologic, and Immunologic Changes after Delivery among Women Receiving Nucleoside Therapy during Pregnancy. Abstract 889, 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. Feb 10-14, 2003, Boston, Massachusetts, USA.
92. **Lambert JS**, McLean KA, Mandalia S. et al. Review of HSV simplex type 1 and 2 type specific serology requests performed at three GUM clinics. BASSH Conference Bath 2004.
93. Nogueira SA, Pinheiro T, Abreu TF, Machado ES, **Lambert JS**. Successful prevention of mother to child transmission with HAART in a developing country. XV International conference on AIDS, Bangkok Thailand 2004 ThPeB7115.
94. Afonso AO, Soares MA, **Lambert JS**, Cunha SM, Oliveira RH, Machado ES. Early emergence of drug resistance mutations in HIV infected children starting dual and triple therapy. XV International Conference on AIDS, Bangkok Thailand 2004. B11856.
95. Machado ES, **Lambert JS**, Afonso AO et al. Alternative, age-related routes of nelfinavir resistance in HIV type 1 infected children under highly active antiretroviral therapy. XV International Conference on AIDS, Bangkok Thailand 2004. WePe5705.
96. Machado ES, **Lambert JS**, Schrago C et al. Higher selective pressure on V3 crown of HIV-infected children with longer survival. XV International Conference on AIDS, Bangkok Thailand 2004. TuPeA4311.
97. Cunha DC Guimaraes MAA, Nogueira SA, Rodrigues R, **Lambert JS**. Co-infection of HTLV-1 and HIV in a cohort of pregnant women in the city of Rio de Janeiro, Brazil. XV International Conference on AIDS, Bangkok Thailand 2004. ThPeB7038.
98. McFarland E, Johnson D, **Lambert JS** et al. Safety and Cell-mediated Immune Response to Prime-Boost Immunization with ALVAC HIV Vaccine in infants born to HIV infected Mothers

(PACTG 326). Abstract R-144 oral presentation, CROI 2005, Boston USA

99. Machado E, Hofer C, Nogueira S, Costa T, **Lambert JS**. Pregnancy outcome in HIV-1 infected women receiving combination therapy prior to conception. Abstract 808, poster discussion session, CROI 2005, Boston USA
100. McDonald C, **Lambert JS**, Nayagam D, Welz T, Poulton M, Welch J. Why are Children Still Being Infected with HIV? Oral presentation, British HIV Association, 12<sup>th</sup> Annual Conference, Brighton, UK, March 2006.
101. **Lambert JS**, Sill AM, Machado ES, Watson D, Devico A. High production of HIV suppressive chemokines correlates with favourable clinical parameters in HIV-infected children receiving antiretroviral therapy. World AIDS Conference 2006, Toronto, Canada.
102. Caswell RJ, Doshi DS, Khoo SH, Gibbons S, Chaponda M, Poulton M, Welch J, McDonald C, **Lambert JS**. Therapeutic Drug Monitoring (TDM): Is it of clinical utility in HIV positive pregnant women? Glasgow HIV Conference 2006.
103. **Lambert JS**, Sill AM, Machado ES, Watson DC, Cunha SM, DeVico AL. High production of HIV suppressive chemokines correlates with favourable clinical parameters in HIV-infected children receiving antiretroviral therapy.
104. Sill AM, **Lambert JS**, Machado ES, Tanuri A, Watson DC, Alfonso AO, da Cunha SC, Oliveira RH, Bowlsbey AL, Devico AL. Higher chemokine secretion in HIV-infected Brazilian children is associated with higher CD4 and lower viral load. Annual Meeting of the Institute of Human Virology, Baltimore, 2006.
105. Brannigan E, Chew N, Keogh M, Hannan M, Sheehan G, **Lambert JS**. A North Dublin **Inner City experience of HIV/Mycobacterial co-infection**. **Glasgow HIV Conference 2006**.
106. Chew N, Muldoon E, Sheehan G, **Lambert JS**, Powderly W. Does Tenofovir Have Any Effect on Haemoglobin Levels? Glasgow HIV Conference 2006.
107. Sukumaran V, McCoy K, Howard R, **Lambert JS**. Cervical cancer screening: a retrospective review of smear results in the setting of a sexual health clinic. Abstract 23, BASHH Spring Meeting, Blackpool 2007.
108. **Lambert JS**, Gallagher D. Abacavir Hypersensitivity and HLA-B\*5701 Screening: Experience in an Inner City Cohort. 13<sup>th</sup> Annual Conference of the British HIV Association (BHIVA) with the British Infection Society (BIS), Edinburgh International Conference Centre, Scotland, April 2007.
109. Kieran J, Cotter A, O'Connor E, Brennan M, Khoo S, Gibbons S, **Lambert JS**. Pharmacological Monitoring in Clinical Practice. 11<sup>th</sup> European AIDS Conference/EACS, Madrid, Spain, October 2007.
110. Howard R, **Lambert JS**. Uptake of Hepatitis B Vaccination in an Infectious Diseases Clinic in Dublin. SSSTDI Meeting, 2007.
111. Brennan M, Coulter-Smith S, **Lambert JS**, Cafferkey M. The Midwife Coordinator: A Vital Role in the DOVE Clinic. NHIVNA, 2007.



112. Howard R, **Lambert JS**. Hepatitis B vaccination uptake and series completion in an urban sexually transmitted infection clinic. Poster presentation. BASHH ASTDA Joint Meeting 2008. Brooklyn, New York City, USA.
113. Wong V, Smith S, **Lambert JS**. Do we still need Intrapartum Zidovudine? Poster presentation: Irish Perinatal Society Meeting, Dublin, 2008.
114. Cotter A, Brown A, Sheehan G, **Lambert JS**, Mallon P. Patients with HIV and Hepatitis C co-infection experience less Atazanavir-induced hyperbilirubinaemia. Poster presentation. BHIVA, Belfast, 2008.
115. McMenamin M, Jackson A, **Lambert JS**, Coulter-Smith S, Jones L, McAuliffe F. Vertical Transmission of Hepatitis C. Poster presentation, American Society of Obstetrics/Gynaecology, Houston, USA, 2008.
116. Jackson V, **Lambert JS**, Brennan M, Kelleher B, Coulter-Smith S, O'Reilly M, Geary M, Grundy KB, Jackson A, Cafferkey M. The Prevalence of Hepatitis C Among Pregnant Women Attending an Irish Maternity Hospital: An Evaluation of Universal Antenatal Screening. Summer Scientific Meeting, Faculty of Public Medicine, Royal College of Physicians, Dublin, 2008.
117. Kearney, F, **Lambert JS**, Mallon P, Sheehan G, Codd M.4, Breiden J, O' Connor E, McConkey S, Mulcahy F, Powderly WG. The Aging HIV Population: Comparison of Patients  $\geq 50$  with those  $< 50$  in the Dublin HIV Cohort Study. Submitted to the Irish and British Geriatric Society meetings, May 2008.
118. Chew N, Doran P, McConkey S, **Lambert JS**, Sheehan G, Powderley W. HIV-Associated Osteoporosis in North Dublin. Mater Misericordiae University Hospital, University College Dublin and Beaumont Hospital, Dublin.
119. **J.S. Lambert**, V. Jackson, M. Brennan, B. Kelleher, S. Coulter-Smith, M. O Reilly, M. Geary, K. B. Grundy, A. Jackson, M. Cafferkey. The Prevalence of Hepatitis C in Pregnancy: An Evaluation of Universal Antenatal Screening at an Irish Maternity Hospital. 48th Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington, DC, 25-28 October 2008.
120. **J.S. Lambert**, L. Else, V. Jackson, S. Gibbons, M. Brennan, J. Kieran, J. Breiden, S. Coulter-Smith, S. Khoo. Therapeutic Drug Monitoring of Atazanavir in pregnancy. The 9th International Congress on Drug Therapy in HIV Infection, Glasgow, 9-13 November 2008
121. V. Jackson, L. Else, S. Khoo, S. Gibbons, M. Brennan, E. O Connor, N. Boyle, C. Fleming, S. Coulter-Smith, **J.S. Lambert**. Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy. The 9th International Congress on Drug Therapy in HIV Infection, Glasgow, 9-13 November 2008
122. Ogunlewe, O. Coulter-Smith, M. Cafferkey, V. Jackson, M. Brennan, B. Kelleher, K.B Grundy, **J.S. Lambert**. The Prevalence Of Hepatitis B In Pregnant Women Attending The Rotunda Hospital 2006-07. O. Junior Obstetric & Gynaecology Society Annual Scientific Meeting, Royal College of Physicians, Dublin, 28 November 2008.

123. Olatunbosun,F. Jackson V, **Lambert JS**, Brennan M, Cafferkey M, Geary M, Malone FD, Coulter-Smith S. Impact of viral infection and substance abuse in pregnancy on perinatal outcome. Junior Obstetric & Gynaecology Society Annual Scientific Meeting, Royal College of Physicians, Dublin, 28 November 2008
124. Geary M, Coulter-Smith S, Cafferkey M, Jackson V, Brennan M, Kelleher B, O Reilly M, Grundy KB, Jackson A, **J.S. Lambert**. *Universal Antenatal Screening For Hepatitis C At An Irish Maternity Hospital* SMFM 29th Annual Meeting in San Diego. 26-31 January 2009
125. Kent E, Akaawi, R, Jackson V, Brennan M, Coulter-Smith S, **Lambert JS**, Geary M, Malone FD. Clinical Risk Factors are not Predictive of Hepatitis C PCR Positivity. SMFM 29th Annual Meeting in San Diego. 26-31 January 2009
126. Satchell C, Cotter A, O'Connor E, Peace A, Tedesco T, Clare A, **Lambert JS**, Sheehan G, Kenny D, and Mallon P. A Case Control Assessment of Platelet Function in HIV-1+ and HIV-1- Individuals. 16<sup>th</sup> Conference on Retroviruses & Opportunistic Infections. Montreal, 8-11 February 2009
127. Ciprike, V. Jackson V, Cafferkey M, Coulter-Smith S, Brennan M, Grundy KB, Eogan M, **Lambert JS**. An Audit of Syphilis Serology in Pregnant Women Attending the Rotunda Hospital 2005-2008. International Meeting of the Institute of Obstetricians & Gynaecologists, Royal College of Physicians, Dublin, 27 February 2009
128. Ciprike V, Jackson V, Cafferkey M, Coulter-Smith S, Brennan M, Grundy KB, Eogan M, **Lambert JS**. An Audit of Syphilis Serology in Pregnant Women Attending the Rotunda Hospital 2005-2008. Irish Perinatal Society Annual Meeting, Carton House, Kildare, 20 March 2009
129. Brennan L, Grundy K, Beckett M, O Connell M, Fitzgibbon A, Brennan M, **Lambert JS**, Clarke T, Cafferkey M. Stethoscopes: Potential Reservoirs For The Spread Of Nosocomial Infections. The Joint Faculty of Paediatrics and Welsh Paediatric Society Meeting, Sheraton Hotel, Fota Island, Cork, 14 - 16 May 2009
130. **Lambert JS**, Eogan M, Jackson V, Brennan M, Ciprike V, Gleeson J, Grundy KB, Coulter-Smith S, Cafferkey M. A 2-year review of infections in pregnancy at a busy inner city maternity hospital. The Infectious Diseases Society of Ireland Annual Scientific Meeting, Dublin 11-12 June 2009.
131. J. Low, D. Crowley, M. Nicholls, W. Cullen, J. Flanagan, N. Glover, **Lambert JS**. Treatment of Hepatitis C Infected Patients in a Community Based Drug Treatment Service in Partnership with Hospital Based Specialist Services. MDSA 30180, UCD School of Medicine and Medical Science (SMMS) Summer Student Research Elective 2009.
132. Swan D, Cullen W, Long J, Flanagan J, Carr O, Helena L, Keating S, Keaveney M, **Lambert JS**, Mc Cormick A, Moloney J, Perry N. A qualitative exploration of coping strategies deployed by injecting drug users with Hepatitis C. Hepatitis C 3<sup>rd</sup> International Conference, 17-19 June 2009, Dublin Castle, Ireland. (also presented at the AUDGPI Annual Scientific Meeting 2010 and the Psychology, Health and Medicine 7<sup>th</sup> Annual Conference 2010).
133. Brennan M, Eogan M, Jackson V, **Lambert JS**, Gleeson J, Coulter-Smith S, Devitt S, Cafferkey M. .A Review of a CMS Co-ordinated Dedicated ID Clinic at a Busy Inner City

Maternity Hospital. The INO Annual Midwifery Conference, Slieve Russell Hotel, 15 October 2009

134. **Lambert JS**, Eogan M, Jackson V, Brennan M.,Ciprike V, Gleeson J, Grundy KB, Coulter-Smith S, Cafferkey M. .A 3-year Review of infections in pregnancy at a Busy Inner City Maternity Hospital. BHIVA Conference, Manchester, 20<sup>th</sup> to 23<sup>rd</sup> April 2010
135. **Lambert JS**, Else L, Jackson V, Breiden,J, Gibbons S, Dickinson L, Back D, Brennan M, Weldridge C, Coulter Smith S, Khoo S. The use of Darunavir/ritonavir once daily regimen in two pregnant women. Submitted for IAS Vienna conference, 2010
136. Boyle C, Wilson A, Treacy G, Sheehan G, **Lambert JS**, Meegan C, Mallon P. Antiretroviral regimen complexity as a predictor of adherence. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010
137. Else LJ, Jackson V, Brennan M, Breiden J, Weldridge C, Coulter-Smith S, Back DJ, Khoo SH, **Lambert JS**. Therapeutic drug monitoring of atazanavir in pregnancy. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010
138. **Lambert,JS**, Else LJ, Jackson V, Dickinson L, .Black DJ, Brennan M, Weldridge C, Coulter-Smith S, Gibbons S, Khoo SH.. The use of darunavir/ritonavir once daily regimen in two pregnant women. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010
139. Satchell CS, Cotter A, O'Connor E, Peace A, Tedesco A, Clare A, **Lambert JS**, Sheehan G, Kenny D, Mallon P. A Case Control Assessment of Platelet Function and HIV-1 Positive and HIV Negative Individuals,2010.
140. Sadlier C, Brown A, **Lambert JS**, Sheehan G, Mallon P. Seroprevalence of Schistosomiasis and Strongyloides Infection in Patients from Endemic Areas attending a European Infectious Diseases Clinic. Helminth ICAAC 2010.
141. Cotter A, Satchell CS, O'Halloran J, .Feeney E, O'Connor E, Sheehan G, **Lambert JS**, Sabin C, Mallon P. The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 Infected Patients, Lipodystrophy 2010 Conference.
142. Swan D, Cullen W, Liddy S, Carr,O, Flanagan J, Irish H, Keating S, Keaveney M, **Lambert JS**, J Long J, Mc. Cormick,A, McKiernan S, Moloney J, Perry N. Obstacles and facilitators of Hepatitis C testing and treatment among people who inject or have injected drugs: the views of service-providers. Hepatitis Conference 2010, Dublin Castle, Ireland.
143. Jackson V, Ferguson W, . Eogan M, Else L, Khoo S, Brennan M, Weldridge C. **Lambert JS**,. Transplacental Transfer of Atazanavir and Neonatal Hyperbilirubinaemia. May 2011, CHIVA Conference, Cardiff, UK.
144. Rock C, Kyithar P, Jackson V, Brennan M, Eogan M, Edwards J, Fleming A, Byrne M, **Lambert JS**. Impaired Glucose metabolism in HIV-1 seropositive pregnant women: a prospective analysis. The 2011 Annual Scientific Meeting of the Infectious Diseases Society of Ireland (IDSI), 7<sup>th</sup>-8<sup>th</sup> June 2011, Kildare Street, Dublin, Ireland.

145. Boyle C, Wilson A, Treacy,G, Sheehan G, **Lambert JS**, Meegan C, PW. Antiretroviral Regimen Complexity as a Predictor of Adherence. The 2011 Annual Scientific Meeting of the Infectious Diseases Society of Ireland (IDS), 7<sup>th</sup>-8<sup>th</sup> June 2011, Kildare Street, Dublin, Ireland.
146. Rock C, Jackson V, Ciprike,V. Brennan M, Ferguson W, Eogan M, **Lambert JS**. Antenatal Screening of Syphilis in Pregnant Women and their Partners- The Importance of Contact Tracing. The 2011 Annual Scientific Meeting of the Infectious Diseases Society of Ireland (IDS), 7<sup>th</sup>-8<sup>th</sup> June 2011, Kildare Street, Dublin, Ireland.
147. Tinago W, O'Halloran J, Macken A, **Lambert JS**, Sheehan G, Mallon PWG. Protease Inhibitors Resistance after Unplanned Treatment Interruptions. EACS Conference, 12<sup>th</sup>-15<sup>th</sup> October 2011, Belgrade, Serbia.
148. Feeney ER, Mc Auley N, O'Halloran JA, Rock C, Low J, **Lambert JS**, Sheehan GJ, Satchell CS, Mallon PWG. The Differential Expression of Cholesterol Metabolism Genes in Monocytes from Treated and Untreated HIV-Infected Subjects Compared to HIV-Negative Controls Suggests Impairment in Reverse Cholesterol Transport and Intracellular Cholesterol Accumulation. EACS Conference, 12<sup>th</sup>-15<sup>th</sup> October 2011, Belgrade, Serbia.
149. Cotter AG, Rock C, Brady J, Healy D, **Lambert JS**, Sheehan G, Sabin CA, Mallon PWG. Seasonal Changes in 25-OH Vitamin D and Parathyroid Hormone in HIV-infected Subjects. EACS Conference, 12<sup>th</sup>-15<sup>th</sup> October 2011, Belgrade, Serbia.
150. **Lambert JS**, Avramovic G, Jackson V, M. Brennan, F.J. Campbell. Investigation into the Reasons for Maternal Default from HIV Care Post-partum. A 3 Year Retrospective Review. EACS Conference, 12<sup>th</sup>-15<sup>th</sup> October 2011, Belgrade, Serbia.
151. Cotter AG, Rock C, Brady J, Sheehan G, **Lambert JS**, Sabin CA, Mallon PWG. Seasonal Changes in and Predictors of Parathyroid Hormone (PTH) Levels in HIV-1 Infected Subjects. Submitted CROI 2012.
152. O'Higgins A, **Lambert JS**,Corcoran S, Jackson V. Determination of the prevalence of genital *Chlamydia trachomatis* infection in patients ages 25 years and under attending the Rotunda Hospital. Biannual Perinatal Audit & Research Meeting, 29<sup>th</sup> June 2012.
153. O'Higgins A, Jackson V, Connolly G, Corcoran S, **Lambert JS**. Screening for Asymptomatic Urogenital *Chlamydia Trachomatis* Infection at a Large Dublin Maternity Hospital: Results of a Pilot Study. JOGS session of the Irish College of Obstetrics, Gynaecology and Perinatal Medicine. 2012 Dec 1<sup>st</sup>.
154. Klimas J, Field CA, Anderson R, Barry J, Bedford D, Bourke M, Bury G, Corrigan G, Doyle J, Flanagan J, Gallagher H, Geoghegan N, Harkin K, Keenan E,**J.S. Lambert**, Lyons S, McAuliffe R, McCann ME, McCormick A, O'Driscoll D, O'Gara C, Perry N, Smyth BP, Weldon F, Cullen W. Problem Alcohol use among problem drug users : Development of Clinical Guidelines for General Practice. 3<sup>rd</sup> ACAMH SIG Research Day, 28<sup>th</sup> September, Limerick, Ireland.
155. Yeung SJ, Breslin T, **Lambert JS**. Use of Post Exposure Prophylaxis after Blood Borne Virus Exposure in an Inner City Emergency Department. Irish Association for Emergency Medicine. 2012 Oct 20<sup>th</sup>.

156. Varughese A, Eogan M, Bergin S, Byrne D, Corcoran S, Ferguson W, Lawless M, **Lambert JS** . A Rare Case Of Primary Cytomegalovirus (CMV) Infection In a HIV Positive Pregnant Patient. 2nd Irish Congress of Obstetrics, Gynaecology and Perinatal Medicine, 30th Nov - 1st December 2012. Druids Glen .Co Wicklow.
157. Monteith C, Eogan M, Cooley S (Rotunda Hospital) **Lambert JS**, Kelleher B, Ní Áinle F, Hepatitis C Associated Thrombocytopenia In Pregnancy: Pregnancy Management and Morbidity. 2nd Irish Congress of Obstetrics, Gynaecology and Perinatal Medicine, 30th Nov - 1st December 2012. Druids Glen, Co Wicklow.
158. Monteith C, Varughese A, Campbell S, Gleeson J, Cooley S, **Lambert JS** (Rotunda Hospital), Kelleher B, Ní Áinle F, Eogan M. A Review of a High Risk Group of Patients for VTE On Prophylactic LWMH. 2nd Irish Congress of Obstetrics, Gynaecology and Perinatal Medicine, 30th Nov - 1st December 2012. Druids Glen. Co Wicklow.
159. Tinago W, Coghlan E, Macken A, Doaks B, McAndrews J, **Lambert JS**, Sheehan G, Mallon PW. Analysis of Expanded T-cell Subsets and Associations with CD4:CD8 ratio in an Ambulatory in HIV-infected Population. Submitted to CROI 2013.
160. **Lambert JS**, V Jackson, M Lawless, W Ferguson, M Eogan, M Brennan, L Else, S Khoo. Transplacental Passage of Atazanavir and Neonatal Hyperbilirubinaemia. 14th International Workshop on Clinical Pharmacology of HIV Therapy 22 – 24 April 2013, Amsterdam, The Netherlands
161. Ali A, Glennon K, Kelleher B, Eogan M, Jackson V, Brennan M, Lawless M, Ferguson W, **Lambert JS**. Five year retrospective review of antenatal Lamivudine (LAM) to reduce the perinatal transmission of Hepatitis B (HBV). Presented at the British Maternal and Fetal Medicine Society 16TH Annual Conference, 26th April 2013, Dublin. Printed in Arch Dis Child Fetal Neonatal Ed 2013;98:Suppl 1 A42-A43 doi:10.1136/archdischild-2013-303966.144
162. Varughese A, . Jackson V, .Cafferkey M, Brennan M, Lawless M, .Ciprike V, Eogan M, Ferguson W, Coulter- Smith S, **Lambert JS**.. Syphilis Serology in Pregnant Women Over a Period of 7 Years (2005–2011) in a Large Maternity Hospital in Dublin, Ireland. Presented at the British Maternal and Fetal Medicine Society 16TH Annual Conference, 26th April 2013, Dublin. Printed in Arch Dis Child Fetal Neonatal Ed 2013;98:Suppl 1 A53 doi:10.1136/archdischild-2013-303966.180
163. **Lambert JS**, Jackson V, Lawless M, Ferguson W, Eogan M, Brennan M, Else,L, Khoo.S. Placental Transfer of Atazanavir and Neonatal Hyperbilirubinaemia. 7<sup>th</sup> Annual Conference of the Children’s HIV Association (CHIVA), Friday 10 May 2013, The Queen’s Hotel, Leeds
164. **Lambert JS**, V Jackson, M Lawless, W Ferguson, M Eogan, M Brennan, L Else, S Khoo. Atazanavir in pregnancy: transplacental transfer and neonatal hyperbilirubinaemia. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention 30 June– 3 July 2013, Kuala Lumpur, Malaysia
165. **Lambert JS**, V Jackson, L Else, M Lawless, W Ferguson, M Eogan, G McDonald, D Le Blanc, M Brennan, S Khoo .Transplacental transfer of Atazanavir and the incidence of neonatal hyperbilirubinaemia. 14th European AIDS Conference/EACS Brussels, Belgium from October 16-19, 2013.

166. C. Finnegan, R. Moore, M. Lawless, V. Jackson, M. Eogan, **Lambert JS**. An audit of compliance with glucose tolerance testing among HIV infected pregnant women taking protease inhibitors. Lifespan Diabetes Research November 14th 2013 – World Diabetes Day The Pillar Room, Rotunda Hospital, Dublin
167. Colbers A, Hawkins D, Hidalgo-Tenorio C, Van der Ende I, Kabeya K, Gengelmaier A, Weizsäcker K, **Lambert JS**, Rockstroh J, Burger D. Effective Exposure to Atazanavir during Pregnancy, Regardless of Tenofovir Use. Accepted to CROI 2014.
168. **Lambert JS**. Incidence of gestational diabetes mellitus (GDM) in a cohort of HIV positive pregnant women. Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) 1–4 April 2014, Arena and Conference Centre, Liverpool, UK
169. O'Connell S, O'Connor C, Hare D, Yeung SJ, Synnott K, **Lambert JS**, Sheehan G, Poynton A, Timlin M, Mallon P. Safety and Efficacy of Out-patient Parenteral Antimicrobial Therapy (OPAT) for Spinal infections, ECCMID conference, 10<sup>th</sup>–13<sup>th</sup> May 2014, Barcelona.
170. **Lambert JS**; Jackson V; Else L; Lawless M; McDonald G; Le Blanc D; Patel A; Stephens K; Khoo S. Darunavir pharmacokinetics throughout pregnancy and postpartum. HIV Drug Therapy, 2-5 November 2014, Glasgow, UK.
171. O'Halloran JA, Herlihy T, Macken A, Rainford L, **Lambert JS**, Sheehan GJ, Mahon NG, Lawler LP, Mallon PWG. Enhanced, not inhibited monocyte cholesterol efflux characterises untreated HIV. CROI 2015, February 23- 26, 2015, Washington State Convention Center, Seattle, Washington, USA.
172. McGellrick P, Ferguson W, Jackson V, Eoghan M, Lawless M, Ciprike V, Varughese A, Coulter-Smith S, **Lambert JS**. Syphilis serology in pregnancy: an eight- year study (2005-2012) in a large teaching maternity hospital in Dublin, Ireland. International journal of STD & AIDS. Int j std aids online first, published on March 30, 2015 as doi: 10.1177/0956 462 4155 80226
173. **Lambert JS**. *Changing incidence of perinatally acquired infection in an era of changing antiretroviral therapy to HIV infected pregnant women in Eastern Cape, South Africa*. 9<sup>th</sup> Annual conference of the Childrens HIV Association (CHIVA) 2015, Stamford Court, University of Leicester. Friday 22 May 2015
174. V Linder, C Goldswain, **Lambert JS**, V Jackson, G Boon, K Harper, C Carty. *Lamivudine monotherapy as a safe option for HIV infected children with challenging circumstances?* New evidence from a large South African cohort. Poster abstract CHIVA, 2015
175. Waqas S., O'Connor M., Levey C., Mallon P., Sheehan G., Patel A., Avramovic G., **Lambert JS**. *Experience of Dolutegravir (DTG) in HIV Infected Treatment Naïve Patients from a Tertiary Care University Hospital in Ireland*. Poster abstract, EACS 2015.
176. Ni Cheallaig, C., **Lambert J.**, Murphy C., O'Carroll A., Farrell J., Patel A., McHugh, T., Avramovic G., Cullen W. (2016). *The Dublin Hepcheck Study: Community based testing of HCV by point of care OraQuick® HCV saliva test in homeless populations*. EASL, Barcelona, Spain, 13-17 April 2016,

177. **Lambert J.**, Murphy C., Patel A., McKenna-Barry M., Crowley, D., Stewart S., Farrell J., Cullen W. (2016) *Opportunistic Fibrosan® testing in a Dublin general practice (GP) managing opiate substitution therapy: The Hepcare study*. EASL, Barcelona, Spain, 13-17 April 2016.
178. *Transition of HIV + Adolescents into Adult care: How can we make it better?* 11<sup>th</sup> International Conference on HIV Treatment and Prevention Adherence, Poster abstract presentation at the Diplomat Hotel in Fort Lauderdale, Florida, May 9-11<sup>th</sup>, 2016.
179. McCombe G, Henihan AM, Llimas J, Swan, Anderson R, Leahy D, **Lambert JS**, Cullen W. *HCV prevalence and treatment among patients attending primary care for opioid agonist treatment*. Poster abstract, IDSI 9<sup>TH</sup> Annual Scientific Meeting, Croke Park Conference Centre, Dublin, Ireland, 12-14<sup>th</sup> May 2016.
180. **Lambert JS**, Avramovic G, McCombe G, Stewart S, Cullen W. *Integrating Primary and Secondary Care to Optimise Hepatitis C treatment: Implementation and Evaluation of a Multidisciplinary Educational Symposium*. Poster Abstract. IDSI 9<sup>th</sup> Annual Scientific Meeting. Croke Park Conference Centre, Dublin, Ireland, 12-14<sup>th</sup> May 2016.
181. **Lambert JS**, Murphy Carol, O'Carroll A, Farrell J, Patel A, Avramovic G, McCombe G, Cullen W. *Community based testing of HCV saliva test in homeless populations* . Poster Abstract. IDSI 9<sup>th</sup> Annual Scientific Meeting, Croke Park Conference Centre Dublin, Ireland, 12-14<sup>th</sup> May 2016.
182. Byrne N, Cormican M, Deely H, Delappe N, Downes P, Ennis O, Igoe D, **Lambert JS**, O'Dea S, O'Halloran J, O'Loughlin N, Ward M, Quinlan M, Cooney F. *Sexual transmission of shigellosis among MSM in Dublin*. Poster presentation. IDSI 9<sup>TH</sup> Annual Scientific meeting, Croke Park Conference centre, Dublin, Ireland, 12-14<sup>th</sup> May 2016.
183. Ni Cheallaig, C., **Lambert JS.**, Murphy C., O'Carroll A., Farrell J., Patel A., Avramovic G., McCombe G., Cullen W. (2016) *Community based testing of HCV by point of care OraQuick® HCV saliva test in homeless populations*. Infectious Diseases Society of Ireland; Dublin, Ireland
184. Crowley D, Murphy C, Farrell J, Stewart S, Keegan D, **Lambert J**, Cullen W. *To evaluate the effectiveness of an opportunistic outreach fibroscanning service to a community based drug treatment clinic and general practice in Dublin*. 5<sup>th</sup> International Radisson Blu Scandinavia Hotel, Oslo, Norway, 7<sup>th</sup> -9<sup>th</sup> September 2016.
185. Crowley D, Murphy C, McHugh T, Farrell J, Stewart S, McCombe G., Cotter A, Cullen W, **Lambert J.S.** (2016) *To evaluate the effectiveness of an opportunistic outreach fibroscanning service to a community based drug treatment clinic in Dublin*. SSA 2016- Society of the Study of Addiction, York, UK.
186. Cullen W., McCombe G., Swan D., O'Connor E., Murphy C., Avramovic G., **Lambert J.S.** (2016) *HepLink: An Overview*. Irish Street Medicine Symposium, Cork, Ireland. Lambert, J. "(2016) *Seek and Treat and Hepcare Europe*. Irish Street Medicine Symposium, Cork, Ireland, 24<sup>th</sup> September 2016

187. *Short term Maternal and Fetal Outcomes in the Context of Option B+ Strategy in South Africa: Findings from Prospective Cohort Study*- Oral Presentation. .International AIDS conference Durban, South Africa. 18<sup>th</sup> -22<sup>nd</sup> July 2016.
188. Adeniyi Oladele V, Selanto N, Goon D T, Ajayi A L, Carty C, Hofmeyer Justus, Boon Gerry, **Lambert JS**. *The cascade of care of pregnant women on highly active antiretroviral therapy in Eastern Cape, South Africa: implications for the elimination of mother- to- child transmission of HIV*. Poster presentation. International AIDS conference Durban, South Africa. 18<sup>th</sup>-22<sup>nd</sup> July 2016.
189. Pierre R.B, Moore J, Carty C.R, Picone M, Avramovic G, D'Erect M, Christie, **Lambert JS**. *The Passages Project Jamaica: Initial observations related to transition*. 21<sup>st</sup> International AIDS conference, Durban, South Africa, 18<sup>th</sup> - 22<sup>nd</sup> 2 July 2016.
190. Oprea C, Carty C.R, Lanache L, Luca A, Picone M, Eredita M.D, Sidloyi L, **Lambert JS**. *The Passages Project Romania: Initial observations related to transition from adolescent to adult HIV care*. 21<sup>st</sup> International conference Durban, South Africa. July 18-22, 2016.
191. Bosha E, Carty CR, Sidloyi L, **Lambert J S**, Adeiniyi Oladele V, *Can smoking and alcohol cessation prior to pregnancy close the gap to eliminate vertical transmission? Evidence from a prospective cohort in the Eastern Cape, South Africa*. 21<sup>st</sup> International AIDS Conference, Durban, South Africa. July 18<sup>th</sup> -22<sup>nd</sup> 2016.
192. Grant-Freemantle Marc C, Mallon Patrick W.G, McCombe Geoff, Macken Alan , Tinago Willard, Avramovic Gordana , O'Halloran Jane , Cotter Aoife G , Sheehan Gerard, **Lambert John S.** *A retrospective analysis of time to non-detectable HIV viral load in fixed dose combination anti-retroviral therapy in HIV-1 patients enrolled in the Mater Misericordiae University Hospital Infectious Diseases (MMUH-ID) cohort*. HIV Drug Therapy 2016, Scottish Exhibition and Conference Centre, Glasgow, Scotland, 23-26 October 2016.
193. Colbers A, Schalkwijk S, Konopnicki D, Gingelmaier A, **Lambert JS**, Van der Ende M, Molto J, Burger D, *Substantially lower rilpivirine plasma concentrations during pregnancy*. Poster abstract Presentation. CROI 2017 Seattle, Washington, USA, 13-16 February 2017.
194. Iqbal N, Murphy C, McHugh T, Singleton A, Keating S, Crowley D, Gallagher H, Savage F, Moloney J, **Lambert J S**, Stewart S. Poster Presentation EASL 2017. *The hidden burden of hepatitis C related advanced liver disease in the community*- The International Liver Congress, Amsterdam, the Netherlands, 19-23 April 2017.
195. HepCheck Hublin; Homeless, Hep C & Competing Priorities- Poster presentation EASL 2017, The International Liver Congress, Amsterdam. The Netherlands, 19-23 April 2017.
196. Iqbal N, Murphy C, McHugh T, Singleton A, Keating S, Crowley D, Gallagher H, Savage F, Maloney J, **Lambert J S**, Stewart S. *The hidden burden of hepatitis C related advanced liver disease in the community*. IDSI 10<sup>th</sup> Annual Scientific Meeting 4th – 6th May 2017 NUI Galway Poster Presentation
197. O'Connor E, Swan D, McCombe G, Murphy C, **Lambert JS** , Avramovic G, Cullen W. Poster Presentation *Integrating Hepatitis C treatment in Primary Care*. IDSI 10<sup>th</sup> Annual Scientific Meeting 4th –NUI Galway 6th May 2017.



198. Crowley D, Betts-Symonds G, Cullen W, Keevans M, Kelly E, **Lambert JS**, Halloran , Mc Hugh T, Mc Kiernan S, Murphy C, Miggin S, Rice J, Van Hout MC. *Evaluating the Impact of Prison based peer workers on Hepatitis C Screening in an Irish Prison*. Poster Presentation. INHSU 2017- 6TH International Conference, Jersey City, New York, USA. 6<sup>TH</sup> -8<sup>th</sup> September 2017.
199. **Lambert JS** Menendez D, Murphy C, McHugh T, O'Carroll A. *Hepatitis C; Homelessness as a barrier to engagement A Barrier to Engagement*. Poster Presentation INHSU 2017- 6TH International Conference, Jersey City, New York, USA. 6<sup>th</sup> -8<sup>th</sup> September 2017.
200. Crowley D, Cullen W, Keevans M, Kelly E, **Lambert JS**, McCombe G, McKiernan S, McHugh T, Miggin S, Murphy C, Van Hout MC. *Blocks and Enablers to Hepatitis C Virus Screening and Treatment- A prisoners Perspective.*, Oral Presentation, INHSU 2017- 6TH International Conference, Jersey City, New York, USA. 6<sup>th</sup>-8<sup>th</sup> September 2017
201. **Lambert JS**, Crowley D Cullen W Keevans M Kelly E McHugh T Mc Kiernan S Miggin S Murphy C Van Hout MC A Report on Phase One of the Prison Based Hepatitis C Seek & Treat Project in Ireland- Poster Presentation INHSU 2017- 6TH International Conference, Jersey City, New York, USA. 6<sup>th</sup>-8<sup>th</sup> September 2017
202. Moloney J, Hawthorne G, McCormick A P, Feeney E, Houlihan D, Keating S, Murphy C, McHugh T, Avramovic G, **Lambert JS** Quinn C. *Near- Patient Serial Transient Elastography (STE) Improves Hepatitis C Treatment Uptake Among Patients On Opioid Substitution Treatment (OST)*- Poster Presentation INHSU 2017- 6TH International Conference, Jersey City, New York, USA. 6<sup>th</sup>-8<sup>th</sup> September 2017.
203. **John S Lambert**, Geoff McCombe, Davina Swan, Nicola Perry. *No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community in Dublin, Ireland*- Abstract accepted for a symposium. 2<sup>nd</sup> European Conference on Addictive Behaviours and Dependencies Lisbon Addiction Conference, Lisbon, Portugal, 24-26 October 2017,
4. *Hepcheck: To enhance HCV screening of PWID* **John S. Lambert**, Carol Murphy, Dee L. Menezes, Walter Cullen, Tina McHugh, Geoff McCombe, Austin O'Carroll.
  5. *HepLink: To integrate primary and secondary care by developing an integrated model of HCV care for PWID*. Davina Swan, Eileen O'Connor, Geoff McCombe, John S. Lambert<sup>2</sup>, Walter Cullen.
  6. *Hepfriend: Developing and cost evaluating a community peer support model to improve access to HCV treatments for PWID*. Tina McHugh, Lar Murphy, Nicola Perry, Belinda Nugent, Passerose Mantoy-Meade, John S. Lambert.
204. Swan D, O'Connor E, McCombe G, Murphy C, **Lambert JS**, Avramovic G, Cullen W, School of Medicine, University College Dublin Infectious Diseases Department, Mater Misericordiae University Hospital. *HepLink: Integrating Hepatitis C Treatment in Primary Care* Abstract - accepted for an oral presentation- 2<sup>nd</sup> European Conference on Addictive Behaviours and Dependencies Lisbon Addiction Conference, Lisbon, Portugal. 24-26 October 2017.
205. Crowley D, Cullen w, Keevans M, Kelly E, Laird E, Mc Kiernan S, Miggins S, Mc Hugh T, Murphy C , Murtagh R, O'Reilly D , Betts- Symonds G , Tobin C , Van Hout M , Lambert JS, 18<sup>th</sup> International Conference on Integrated Care Poster Presentation. THE PREVALENCE OF CHRONIC UNTREATED HEPATITIS C VIRUS INFECTION AND ASSOCIATED RISK FACTORS IN IRISH PRISONERS; A CROSS SECTIONAL STUDY. Utrecht, Netherlands, 23-25<sup>th</sup> May 2018.

206. 18<sup>th</sup> International Conference on Integrated Care. Utrecht, the Netherlands. Poster Presentation. *HepCare Europe- HepCheck reaching Vulnerable Populations*, 23-25<sup>th</sup> May 2018.
207. HepCare Europe- *Development of HepFriend; A Dublin based Hepatitis C Peer Support Model*. Oral Presentation. 18<sup>th</sup> International Conference on Integrated Care, Utrecht, the Netherlands. 23-25<sup>th</sup> May 2018.
208. **Lambert JS**, Cullen W, Oprea C, Story A, Sanchez JM, Surey j. *HEPCARE EUROPE: HEPCHECK; POINT OF CARE TESTING IN VULNERABLE* Poster Presentation INHSU Lisbon Portugal, 19<sup>th</sup> -21<sup>st</sup> September 2018.
209. Crowley D, Cullen W, Keevans M, Kelly E, Laird E, Mc Kiernan S, Miggins S, Mc Hugh T, Murphy C, Murtagh R, O'Reilly D, Betts- Symonds G, Tobin C, Van Hout M, **Lambert JS** *THE PREVALENCE OF CHRONIC UNTREATED HEPATITIS C VIRUS INFECTION AND ASSOCIATED RISK FACTORS IN IRISH PRISONERS; A CROSS SECTIONAL STUDY*. Poster Presentation INHSU, Lisbon Portugal, 19<sup>th</sup> -21<sup>st</sup> September 2018.
210. McElroy K, O'Shea A, O'Carroll A, **Lambert J**, O' Reilly F, Moran C<sup>4</sup>, O'Connor M, Kiely B, Farrell J *TREATMENT OF HEPATITIS C IN THE HOMELESS DRUG USING POPULATION: AN INNOVATIVE SHARED CARE APPROACH REMOVING BARRIERS TO ACCESS* Poster Presentation INHSU Lisbon Portugal, 19<sup>th</sup> -21<sup>st</sup> 2018.
211. Moloney J, McCormick PA, **Lambert J S**, Stewart S, Quinn C, McHugh T, Hawthorne G, *TEN-YEAR MORTALITY DEMONSTRATES THAT OPIOID SUBSTITUTE PATIENTS, WITH HIGH ALCOHOL INTAKE, REQUIRE EARLY LINKAGE TO HEPATITIS C (HCV) TREATMENT*. Poster Presentation INHSU, Lisbon Portugal. 19<sup>th</sup> -21<sup>st</sup> September 2018.
212. Kelly A, Dean J, O'Leary A, Stewart S, Courtney G, Fanning LJ, Feeney E, Kelleher B, **Lambert JS**, Lee J, McConkey S, McCormack PA, McKiernan S, Murray F, Norris S, Crosbie O, Houlihan DD, Bergin C, De Gascun CF, *Direct-Acting Antiviral Treatment Failures and Resistance Associated Substitutions in Hepatitis C Virus Infection in Ireland*. Oral Presentation. HCV2018 RDS, Dublin, Ireland, October 8<sup>th</sup>-11<sup>th</sup> 2018.
- 216 **John S Lambert** (Mater Misericordiae University Hospital/UCD) Walter Cullen (School of Medicine, University College Dublin, Dublin, Ireland) Alistair Story (University College London Hospital) Julian Surey (Institute of Global Health, University College London, UK) Cristiana Oprea (Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania) Juan Macias (Hospital Uni) *HEPCARE EUROPE: Hepcheck; Reaching vulnerable populations* Poster Presentation. HCV 2018, RDS, Dublin, Ireland. October 8<sup>th</sup>-11<sup>th</sup> 2018.
- 217 **Lambert JS**, Cullen W, Story A, Surey J, Oprea C, Macias J, and the HepCare Europe Consortium. *HepCare Manifesto* Poster Presentation HepHIV 2018 Bucharest, Romania, 28-30 January 2019.
- 218 **Lambert JS**. Avramovic G, Barror S, Iglesias M, Ianache I, Naughton AM, Horan A, Oprea C, Surey J, Story A, Macias J, Cullen W, Tinago W. *HepCheck- Enhancing HCV Identification and Linkage to Care for Vulnerable Populations through Intensified Outreach Screening*. Poster Presentation. HepHIV 2019 Bucharest, Romania 28-30 January 2019.
- 219 Eithne Nic An Riogh, Davina Swan, Geoff McCombe, Eileen O'Connor, Gordana Avramovic, Juan Macias Sanchez, Cristiana Oprea, Alistair Story, Julian Surey, Peter Vickerman, Zoe Ward,

**John S Lambert**, Willard Tinago, Irina Ianache, Maria Iglesias, Walter Cullen *HepLink: Findings from a multi-centre Observational Study in Primary and Community Care* Poster Presentation HepHIV 2018 Bucharest, Romania, 28-30 January 2019.

220. McElroy K, Dwyer R, O'Shea A, McDonnell, O'Carroll A, O'Reilly F, Farrell J, Murphy T, Moran C, O'Connor M, **Lambert JS**. *Treatment of Hepatitis C in Homeless Drug Using Population: An Innovative Shared Care Approach Removing Barriers to Access*. Poster Presentation HepHIV 2018 Bucharest, Romania, 28-30 January 2019.
221. McGinty T, Miles S, Tinago W, Sabin C, Landay A, Martinson J, Prior C, Doak B, DeGascun C, Burke D, Macken A, Sheehan G, **Lambert JS**, Cotter A, Mallon P. *Immunosenescence in HIV is associated with CMV status and lower CD4:CD8 ratio*. Poster Presentation CROI 2019, Washington State Convention Centre, Seattle, USA, 04-07 March 2019.
222. S O Loughlin, G Avramovic, G McCombe, W Cullen, **JS Lambert**. *The use of TickPlex plus in diagnosing Lyme Disease: A comparison to standard testing methods*. Poster presentation. School of Medicine Summer Students Research Programme 2019 UCD School of Medicine, University College Dublin, Belfield, Dublin 4.
223. CHS Quay, G Avramovic, W Cullen G. McCombe, **JS Lambert**. *Hepatitis C care standardized, adapted across the EU and compared to other initiatives*. Poster presentation, School of Medicine Summer Students Research Programme 2019 UCD School of Medicine, University College Dublin, Belfield, Dublin 4.
224. O. Robineau, S. Esser, C. Spinner, C. Stephan, J. Brunetta, J. De Wet, A. Wong, B. van Welzen, **J.S. Lambert**, M. Heinzkill, H. Ramroth, S. Sahali, H. Tossonian, A. Torres Cornejo, N. Marshall, R. Haubrich, D. Thorpe *The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH)*. AIDS2020 Poster - BICSTaR Virtual Conference 6-10<sup>th</sup> July 2020.
225. Renato Maserati, Arya Khosravi, Sanjay Bhagani, Charalambos Gogos, Francesco Barchiesi, Zeno Pasquale, Marta Mora Rillo, **John S. Lambert**, Rachana Palnitkar, Diego Ripamonti, Francesca Torriani, Jason Goldman, Susanna K. Tan, Laura E Telep, Hal Martin, Alan Smith, Adam DeZure, Yang Zhao, Anand P. Chokkalingam, Anu O. Osinusi, Diana M. Brainard, Elisa Marchionni, Diego Lopez de Castilla. *Exposure to Remdesivir Through Compassionate Use: Safety and Efficacy in 163 Patients*. International Aids Society (IAS) COVID-19 Virtual Conference 10-11 July 2020.

## **OUTREACH ACTIVITIES**

1. 2005-2011 CHIVA South Africa- Volunteer, mentoring of doctors and nurses on ARV rollout for pregnant women and children with HIV.
2. 2005-2011 Baphumelele Project- Capetown South Africa. Support for hospice programme, consultancy for project.

3. 2012-2013 East London- South Africa. Audit of HIV infected children Project.